US20050129746A1 - Fluid-jet medicament delivery - Google Patents
Fluid-jet medicament delivery Download PDFInfo
- Publication number
- US20050129746A1 US20050129746A1 US11/048,368 US4836805A US2005129746A1 US 20050129746 A1 US20050129746 A1 US 20050129746A1 US 4836805 A US4836805 A US 4836805A US 2005129746 A1 US2005129746 A1 US 2005129746A1
- Authority
- US
- United States
- Prior art keywords
- ingestible
- orally
- medicament
- sheet
- fluid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003814 drug Substances 0.000 title claims abstract description 248
- 239000012530 fluid Substances 0.000 claims abstract description 153
- 238000000034 method Methods 0.000 claims abstract description 72
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 6
- 239000002552 dosage form Substances 0.000 claims description 90
- 239000000463 material Substances 0.000 claims description 46
- 230000004888 barrier function Effects 0.000 claims description 34
- 238000004519 manufacturing process Methods 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 21
- 238000007639 printing Methods 0.000 claims description 16
- 230000003213 activating effect Effects 0.000 claims description 11
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims 4
- 229940079593 drug Drugs 0.000 description 22
- 238000010304 firing Methods 0.000 description 20
- 238000003860 storage Methods 0.000 description 19
- 238000010586 diagram Methods 0.000 description 18
- 230000008569 process Effects 0.000 description 18
- 239000000546 pharmaceutical excipient Substances 0.000 description 16
- 239000003826 tablet Substances 0.000 description 11
- 230000007423 decrease Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 230000004913 activation Effects 0.000 description 8
- 238000001994 activation Methods 0.000 description 8
- 238000004891 communication Methods 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 7
- 238000000151 deposition Methods 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 238000002483 medication Methods 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 230000008021 deposition Effects 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 235000012055 fruits and vegetables Nutrition 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 230000002452 interceptive effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000123 paper Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000002313 adhesive film Substances 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000013475 authorization Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000011358 absorbing material Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229940053009 ethyl cyanoacrylate Drugs 0.000 description 1
- FGBJXOREULPLGL-UHFFFAOYSA-N ethyl cyanoacrylate Chemical compound CCOC(=O)C(=C)C#N FGBJXOREULPLGL-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000011112 polyethylene naphthalate Substances 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
- B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
- B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
- B41J2/005—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by bringing liquid or particles selectively into contact with a printing material
- B41J2/01—Ink jet
- B41J2/17—Ink jet characterised by ink handling
- B41J2/175—Ink supply systems ; Circuit parts therefor
- B41J2/17503—Ink cartridges
- B41J2/17513—Inner structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
- B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
- B41J29/00—Details of, or accessories for, typewriters or selective printing mechanisms not otherwise provided for
- B41J29/38—Drives, motors, controls or automatic cut-off devices for the entire printing mechanism
- B41J29/393—Devices for controlling or analysing the entire machine ; Controlling or analysing mechanical parameters involving printing of test patterns
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
- B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
- B41J3/00—Typewriters or selective printing or marking mechanisms characterised by the purpose for which they are constructed
- B41J3/407—Typewriters or selective printing or marking mechanisms characterised by the purpose for which they are constructed for marking on special material
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/13—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Definitions
- the present disclosure relates to fluid-jet medicament delivery. More particularly, the present disclosure relates to applying precise doses of medicament onto an edible sheet using fluid-jet technology.
- Oral administration of pharmaceuticals is one of the most widely used methods to provide effective therapy for a variety of illnesses.
- Many powdered medications are typically administered orally to a person in a dosage form such as tablets or capsules, while still others are in liquid form.
- the release of orally administered medications falls into two broad categories, buccal or sublingual administration, and oral dissolution.
- enteric coated tablets that release the medication in the intestinal tract of the patient.
- many individuals suffer from chronic health problems that require the regular administration of medicaments. Diseases such as diabetes, allergies, epilepsy, heart problems, AIDS, and even cancer requires the regular delivery of precise doses of medicaments if patients are to survive over long periods of time.
- Such chronic treatment creates the need to regularly obtain additional medication. This can be extremely troublesome for those patients that lack the mobility to easily travel to a pharmacist to refill medications, such as the elderly and infirm.
- a method and a dosage form that provides the ability to make custom doses, outside of the large pharmaceutical manufacturing plants, is desirable.
- typical methods for manufacturing include the mixing of the pure drug with various other substances commonly referred to as excipients or diluents that are therapeutically inert and acceptable by regulatory bodies, such as the FDA. Excipients may also protect the drug from deterioration by oxidation, humidity, and light. Palatability can be improved through the addition of flavorants and identification by use of colorants. This mixing process often requires the use of sophisticated, complex expensive machinery. Certain excipients may be needed to improve the flowability of the drug and diluents through the mixing machinery. Therefore, a method and dosage form that reduces the mixing of the active drug with other substances, and utilizes less complex and expensive machinery would also be desirable.
- Drugs with a narrow therapeutic range must also be precisely dosed. If the patient falls below the range, the desired effect will not occur. However, if the patient is above the range then the risk of toxic effects increases. Clinicians assume the dose units manufactured are uniform and that generic equivalents have equal bioavailability. The many FDA generic formulation rejections and recalls for pharmaceuticals that have too high or low of a drug level, however, are evidence that accuracy and precision are still challenges for pharmaceutical manufacturing.
- FIG. 1 a is a perspective view of a fluid cartridge containing an orally-ingestible medicament
- FIG. 1 b is a perspective view of fluid ejection cartridges held within a carriage
- FIG. 1 c is a perspective view of fluid ejection cartridges and an image acquisition system held within a carriage;
- FIG. 2 a is a perspective view of a orally-ingestible medicament dispensing system
- FIG. 2 b is a perspective view of a orally-ingestible medicament dispensing system with an ingestible sheet tray;
- FIG. 3 is a cross-sectional view of a fluid ejection cartridge
- FIG. 4 a perspective view of an ingestible sheet
- FIG. 5 a is a plan view of an ingestible sheet
- FIG. 5 b is a cross-sectional view of the ingestible sheet shown in FIG. 5 a.
- FIG. 6 a is a cross-sectional view of a method for generating a dosage form
- FIG. 6 b is a cross-sectional view of a method for generating a dosage form
- FIG. 6 c is a cross-sectional view of a method for generating a dosage form
- FIG. 6 d is a cross-sectional view of a method for generating a dosage form
- FIG. 7 a is a perspective view of a process for manufacturing a dosage form
- FIG. 7 b is a perspective view of an encapsulated and unitized single dose
- FIG. 7 c is a plan view of a process for manufacturing a dosage form
- FIG. 8 a is a perspective view of a dosage form to vary the amount of the medicament released over time
- FIG. 8 b is a perspective view of a dosage form to vary the amount of the medicament released over time
- FIG. 8 c is a perspective view of a dosage form to vary the amount of the medicament released over time
- FIG. 9 a is a plan view of a dosage form containing user information
- FIG. 9 b is a plan view of a dosage form containing user information and manufacturing information
- FIG. 10 a is a cross-sectional view of a process for manufacturing a dosage form
- FIG. 10 b is a cross-sectional view of a dosage form manufactured using the process shown in FIG. 10 a;
- FIG. 11 is a block diagram of a medicament dispensing system for the interactive dispensing of a medicament on an ingestible sheet
- FIG. 12 is a flow diagram of an interactive method for generating a dosage form
- FIG. 13 a is a flow diagram showing a more detailed view of the steps for loading materials shown in FIG. 12 ;
- FIG. 13 b is a flow diagram showing a more detailed view of the steps for reading information from materials shown in FIG. 12 ;
- FIG. 13 c is a flow diagram showing a more detailed view of the steps for requesting information shown in FIG. 12 ;
- FIG. 13 d is a flow diagram showing a more detailed view of the steps for specifying information shown in FIG. 12 ;
- FIG. 13 e is a flow diagram showing a more detailed view of the steps for verifying information shown in FIG. 12 ;
- FIG. 13 f is a flow diagram showing a more detailed view of the steps for applying the medicament on the ingestible sheet shown in FIG. 12 ;
- FIG. 13 g is a flow diagram showing a more detailed view of the steps for printing information shown in FIG. 12 .
- the present invention advantageously uses the multi-drop deposition capability of a fluid-jet ejection system to dispense medicaments on an ingestible carrier such as an ingestible sheet.
- a fluid-jet ejection system to dispense medicaments on an ingestible carrier such as an ingestible sheet.
- an ingestible carrier such as an ingestible sheet.
- other methods of activating fluid-jet ejection such as piezoelectric or acoustic activation, may also be used in the present invention.
- the fluid ejection system of the present disclosure includes a drop-on-demand type fluid dispenser.
- the present disclosure provides greater control of the drug dose than a typical diluting and mixing apparatus by producing precise and repeatable doses onto an ingestible carrier.
- Another feature of the present invention is the ability to dispense multiple different pharmaceuticals in varied quantities onto an ingestible carrier.
- the term “medicament” shall mean a substance that treats or prevents or alleviates a disease or illness and/or the symptoms of the disease or illness.
- An example of a medicament is a pharmaceutical substance, such as a drug.
- the term “medicament” can be used to refer to such a substance in pure form, a mixture of the substance with other substances, and/or a solution including the substance.
- An “orally-ingestible medicament” is a medicament intended for intake into the digestive track via the mouth, as opposed to a medicament that is intended to be injected or surgically implanted.
- An orally-ingestible medicament may be configured to be digested and/or otherwise act in one or more of the mouth, throat, stomach, intestines, or any other portion of the alimentary canal.
- a fluid reservoir 128 in the body portion of the fluid ejection cartridge 102 , typically contains a medicament used to generate the pharmaceutical dose and/or an ingestible ink used to generate an image or characters on an ingestible sheet or other carrier used to make a dosage form.
- the fluid reservoir 128 is fluidically coupled, preferably through internal passageways, to a substrate (not shown) that is attached to the back of a nozzle layer 126 .
- the substrate normally contains an energy-generating element or fluid ejector (not shown) that generates the force necessary for ejecting the fluid held in the reservoir.
- Two widely used energy generating elements are thermal resistors and piezoelectric elements.
- the former rapidly heats a component in the fluid above its boiling point causing vaporization of the fluid component resulting in ejection of a drop of the fluid. While the latter utilizes a voltage pulse to generate a compressive force on the fluid resulting in ejection of a drop of the fluid.
- various transducers utilized in drop-on-demand fluid ejection cartridges see Stephen F. Pond, Ph.D. Inkjet Technology and Product Development Strategies , ch 4 (Torrey Pines Research, 2000); and more particularly for thermal inkjet technology see J. Stephen Aden et al., The Third - Generation HP Thermal InkJet Printhead , Hewlett-Packard Journal, vol. 45, no. 1, pg. 41-45, February 1994.
- the substrate (not shown), the nozzle layer 126 , nozzles 124 , and a flexible circuit 125 form what is generally referred to as an ejector head 122 .
- the ejector head 122 includes the substrate (not shown), the nozzle layer 126 and the nozzles 124 .
- the nozzle layer 126 contains one or more nozzles 124 through which fluid, that is contained in a chamber around the fluid ejectors, is ejected by activation of the fluid ejectors (not shown) located in close proximity to the nozzles 124 .
- Each activation of a fluid ejector results in the ejection of a precise quantity of fluid in the form of a fluid drop; thus, the number of activations of the fluid ejector controls the number of drops ejected.
- drop formation see for example Jaime H. Bohorquez et al., Laser - Comparable Inkjet Text Printing , Hewlett-Packard Journal, vol. 45, no. 1, pg. 9-17, February 1994; or William A. Buskirk et al., Development of a High Resolution Thermal Inkjet Printhead , Hewlett-Packard Journal, vol. 39, no. 5, pg. 55-61, October 1988.
- the fluid ejection cartridge 102 described in the present invention can reproducibly and reliably eject drops in the range of from about ten femto-liters to about ten micro-liters depending on the parameters of the fluid ejection cartridge such as the size and geometry of the chamber around the fluid ejector, the size and geometry of the fluid ejector, and the size and geometry of the nozzle.
- the present invention has the ability to accurately dispense a medicament solution with a part per million to a part per billion accuracy. This is particularly advantageous when dispensing expensive medicaments, such as certain hormones, antibiotics, and medicaments derived from some natural products in scarce supply. The accuracy and precision is advantageous when dispensing concentrated substances with high potency.
- a further advantage of utilizing the fluid ejection cartridge 102 of the present invention is a reduction, to less than one percent by weight, in the amount of excess medicament that is dispensed to assure proper label dosage.
- medicament can be accurately applied to a carrier in the form of a plurality of closely sized drops, which include substantially equal amounts of medicament. By controlling the number of drops that are applied, the total amount of medicament can be controlled.
- target dose shall mean the exact amount of medicament that is to be placed onto a carrier, and “therapeutic quantity” is a range of acceptable doses that includes the target dose.
- This embodiment is also advantageous for utilizing a mixture of the medicament and an ingestible ink contained in the fluid reservoir 128 .
- Fluid ejection cartridge 102 can utilize a method of creating discrete sized drops that are independently ejected from a particular nozzle utilizing a particular fluid ejector while maintaining a narrow drop volume distribution.
- the narrow drop volume distribution can be maintained over multiple nozzles each having a separate fluid ejector and fired independently or simultaneously.
- Such a cartridge can be characterized by a very narrow distribution of drop volumes and may have anywhere from a 2 ⁇ , 3 ⁇ or even more narrower drop volume distribution than conventional fluid ejector devices such as hydraulic, air assisted, or ultrasonic nozzles that form a spray of fluid having varying drop sizes.
- the range in drop volume is generally within 10 percent of the targeted or specified value and under steady state conditions can be within about 6 percent or less of the targeted value.
- a medicament can be accurately dispensed with a part per million to a part per billion accuracy.
- the nozzle layer 126 may be formed of metal, polymer, glass, or other suitable material such as ceramic.
- the nozzle layer 126 is formed from a polymer such as polyimide, polyester, polyethylene naphthalate (PEN), epoxy, or polycarbonate.
- the nozzle layer 126 is formed from a metal such as a nickel base enclosed by a thin gold, palladium, tantalum, or rhodium layer.
- the components of the ejector head 122 and the fluid reservoir are formed of materials that are inert to the medicament and/or the ingestible ink which are to be dispensed therefrom.
- inert materials such as glass, ceramic, stainless steel, noble metals, and polymers inert to the medicament are preferred.
- the fluid is selectively expelled from the one or more of the nozzles 124 by electrical signals communicated through electrical contacts 130 and associated conductive traces 132 disposed on the flexible circuit 125 .
- the flexible circuit 125 is typically bent around an edge of the fluid ejection cartridge 102 and secured.
- the electrical traces 132 are routed from the electrical contacts 130 to bond pads on the substrate (not shown) to provide electrical connection for the fluid ejection cartridge 102 .
- a fluid ejector is activated the appropriate number of times to eject a predetermined number of drops.
- An information storage element 133 is disposed on cartridge 102 .
- the information storage element 133 is coupled to a flexible circuit such as the flexible circuit 125 as shown in FIG. 1 a .
- the information storage element 133 is any type of memory device suitable for storing and outputting information that may be related to properties or parameters of the medicament contained within the fluid reservoir 128 .
- the information storage element 133 is a memory chip mounted on the flexible circuit 125 and electrically coupled through the electrical traces 132 to the electrical contacts 130 .
- the information storage element 133 can be encapsulated in its own package with corresponding separate electrical traces and contacts.
- the information storage element 133 When the fluid ejection cartridge 102 is either inserted into, or utilized in, a dispensing system the information storage element 133 is electrically coupled to a controller that communicates with the information storage element 133 to use the information or parameters stored therein.
- a controller that communicates with the information storage element 133 to use the information or parameters stored therein.
- other forms of information storage can also be utilized for the information storage element 133 , such as a bar code or other device that allows storage of information.
- the information storage element 133 can be mounted elsewhere on or within the body of the fluid ejection cartridge 102 with appropriate contacts and electrical connections to access the storage element depending on the particular application.
- the information storage element 133 can also be placed on an off-axis container utilized with semi-permanent ejector heads or cartridges.
- the information storage element 133 may contain information such as the particular medicament or other material contained in the fluid reservoir 128 ; the quantity of material remaining in the fluid reservoir 128 based on the number of drops dispensed or the number of times the fluid ejector has been activated. Other information can include the date of manufacture, inspection dates, quality control information, dispensing system parameters, and customer/patient information.
- the fluid ejection cartridge 102 or more preferably a set of individual fluid ejection cartridges 102 and 103 , capable of ejecting drops of medicament and/or ingestible ink or a combination thereof from ejector heads 122 and 123 are held within a carriage 111 , as illustrated in a perspective view in FIG. 1 b .
- Alternative embodiments can include one or more semi-permanent ejector heads that are replenished from one or more fluidically-coupled off-axis fluid containers, or a single fluid ejection cartridge having one or more fluids available within the fluid ejection cartridge and fluid ejecting nozzles designated for each fluid integrally coupled with each fluid reservoir, or a single fluid ejection cartridge having a mixture of the medicament and ingestible ink.
- the present invention can be satisfactorily employed by at least these alternatives.
- FIG. 1 c An alternate embodiment of the present invention where a carriage 111 ′ contains an image acquisition system 150 is shown in FIG. 1 c .
- the image acquisition system 150 contains a camera 151 and a light source 152 .
- the light source 152 is positioned relative to the camera 151 so that the camera 151 can image these detectable geometric aspects.
- the light source 152 comprises a single source, multiple sources can also be used.
- the light source 152 is preferably a light emitting diode (LED), although other light sources such as light bulbs or lasers can also be utilized.
- LED light emitting diode
- the image acquisition system 150 also contains, a camera and light source, controller 153 that is preferably coupled to a drop-firing controller 214 as shown in FIG. 2 a .
- controller 153 that is preferably coupled to a drop-firing controller 214 as shown in FIG. 2 a .
- the camera controller 153 is correspondingly triggered by the drop-firing controller 214 ; thus activating the camera 151 to gather image information pertaining to a portion of the surface of an ingestible sheet on which either a medicament or ingestible ink has been deposited.
- the camera 151 as shown in FIG.
- 1 c can be any camera that can image the desired qualities on an ingestible sheet such as a camera that captures 2 dimensional images or line scan cameras that capture a narrow-stripped portion of the surface being imaged and these narrow-stripped portions are combined to for a complete two dimensional image.
- the image acquisition system 150 can also be utilized to capture images of information that has been placed on an ingestible sheet prior to deposition of the medicament or ingestible ink. Examples of such information are the composition of the ingestible sheet or results of quality control testing; data on compatibility with the medicaments, i.e. whether the ingestible sheet is compatible or incompatible with medicament being dispensed; patient information such as height, weight, name, age, prescribed dose etc.; expiration dates, temperature and/or humidity sensors, indicating that the ingestible sheet is no longer effective or it has been exposed to an extreme which could hinder its effectiveness.
- image acquisition system 150 is mounted in carriage 111 ′, other arrangements can also be utilized such as mounting the image acquisition system 150 on a separate carriage, or locating the image acquisition system in a different portion of a medicament dispensing system 200 shown in FIG. 2 a.
- FIG. 2 a The essential parts of a medicament dispensing system 200 according to an embodiment of the present invention is shown in a block diagram in FIG. 2 a .
- a platen to which an ingestible sheet 204 such as a starch or glycerin based paper, is transported by mechanisms that are known in the art.
- the carriage 111 is typically supported by a slide bar 213 or similar mechanism within the system 200 and physically propelled along the slide bar 213 to allow the carriage 111 to be translationally reciprocated or scanned back and forth across the ingestible sheet 204 .
- the scan axis, X is indicated by an arrow in FIG. 2 a.
- the carriage 111 scans across the ingestible sheet 204 , and fluid drops are selectively ejected from fluid ejectors disposed within the fluid ejection heads of the set of fluid ejection cartridges 102 and 103 onto the ingestible sheet 204 .
- the power to activate the fluid ejectors is supplied by a power supply 215 .
- the drops are ejected to form predetermined dot matrix patterns, forming both the pharmaceutical dose from the cartridge containing the medicament, and images or alphanumeric characters from the cartridge containing the ingestible ink.
- Rasterization of the data can occur in a host computer such as a personal computer or PC (not shown) prior to the rasterized data being sent, along with the system control commands, to the system, although other system configurations or system architectures for the rasterization of data are possible. This operation is under control of system driver software resident in the system's computer. The system interprets the commands and rasterized data to determine which drop ejectors to fire.
- An arrow in FIG. 2 a indicates the fluid drop trajectory axis, Z, directed from the fluid ejection cartridges 102 and 103 toward the ingestible sheet 204 .
- the ingestible sheet 204 is moved an appropriate distance along the ingestible sheet axis, Y, indicated by the arrow, in preparation for the next swath.
- This invention is also applicable to medicament dispensing systems employing alternative means of imparting relative motion between the fluid ejection cartridges and the ingestible sheet, such as those that have fixed fluid ejection cartridges and move the ingestible sheet in one or more directions, and those that have fixed ingestible sheet and move the fluid ejection cartridges in one or more directions.
- the ingestible sheet 204 is advanced into a fluid ejection area beneath the ejector heads 122 and 123 (shown in FIG. 1 b ) by a sheet positioning mechanism commonly referred to as a sheet positioner or sheet advancer including rollers 217 , a platen motor 216 , and traction devices (not shown).
- a sheet positioning mechanism commonly referred to as a sheet positioner or sheet advancer including rollers 217 , a platen motor 216 , and traction devices (not shown).
- the fluid ejection cartridges 102 and 103 are incrementally drawn across the ingestible sheet 204 on the platen by a carriage motor 212 in the ⁇ X direction, perpendicular to the Y direction of entry of the medium.
- the platen motor 216 and the carriage motor 212 are typically under the control of the sheet and cartridge position controller 218 .
- An example of such a positioning and control apparatus may be found described in U.S. Pat. No. 5,070,410.
- the ingestible sheet 204 is positioned in a location so that the fluid ejection cartridges 102 and 103 may eject drops of fluid onto the ingestible sheet 104 as required for the particular dose being generated, and the particular data being written that is input to the drop-firing controller 214 of the medicament dispensing system 200 . These drops of fluid are expelled from selected orifices in the ejector heads 122 , 123 (as shown in FIG.
- the ingestible sheet 204 is conventionally incrementally advanced by the position controller 218 and the platen motor 216 . Once the fluid ejection cartridges have reached the end of their traverse in the X direction on the slide bar 213 or similar support mechanism, they are either returned back along the slide bar 213 while continuing to eject fluid or returned without ejecting.
- the ingestible sheet 204 may be advanced by an incremental amount equivalent to the width of the fluid-ejecting portion of the fluid-ejecting head or some fraction thereof related to the spacing between the nozzles.
- Control of the ingestible sheet 204 , positioning of the fluid ejection cartridge, and selection of the correct fluid ejectors for creation of both the medicament dose and the image or character written is determined by the position controller 218 and the drop-firing controller 214 .
- the controllers may be implemented in a conventional electronic hardware configuration and provided operating instructions from conventional memory 219 .
- the medicament dispensing system 200 can also contain a heater 221 coupled to a heater controller 220 as shown in FIG. 2 a .
- the heater 221 heats the ingestible sheet 204 to remove water and other solvents deposited on the ingestible sheet 204 after deposition of the medicament or ingestible ink.
- the heater also contains a temperature sensor (not shown) that is coupled to the heater controller 220 to maintain the ingestible sheet 204 at the appropriate temperature. The particular temperature that the temperature sensor maintains depends on the particular medicament or ingestible ink being dispensed, and on the particular ingestible sheet 204 being utilized.
- the heater 221 is located above the rollers 217 as depicted in FIG. 2 a the heater can also be located in other portions of the medicament dispensing system 200 such as underneath the ingestible sheet 204 in front of the rollers 217 .
- FIG. 2 b A perspective view of an alternate embodiment of the present invention where the medicament dispensing system 200 includes an ingestible sheet tray 299 is shown in FIG. 2 b .
- the tray 299 holds separate ingestible sheets 204 ′ that are advanced into the fluid ejection area beneath ejector heads (not shown) by rollers 217 ′ and other mechanisms as described above in FIG. 2 a .
- the tray 299 holds from 1 to about 250 sheets, however, depending on the particular system, ingestible sheet, and medicament being utilized, the tray 299 may hold more than 250 sheets.
- the apparatus described above makes unique use of an automated fluid ejecting device, having at least one medicament supply in a reservoir or chamber and at least one, and preferably, a plurality of fluid ejectors in an array, each ejector dispensing a precise volume of fluid in essentially individual droplets on each activation of the fluid ejector.
- This arrangement enables the quantity of the medicament dispensed to be varied in a specified area of the ingestible sheet thereby enabling either custom, or a wide range of doses to be more easily prepared.
- the apparatus or system as depicted in FIGS. 2 a and 2 b may be used in a manufacturing environment, a pharmacy, or even in other dispensing locations such as in a hospital, home etc. to automatically prepare pharmaceutical doses in response to patients needs.
- FIG. 3 A cross-sectional view of an alternate embodiment of the present invention where a fluid ejection cartridge 302 includes three fluid reservoirs 327 , 328 , and 329 contained within a cartridge body 334 is shown in FIG. 3 .
- a substrate 336 is attached to the outer surface of the cartridge body 334 , and includes three groups of fluid ejectors 346 , 346 ′ and 346 ′′, in fluid communication with the three fluid reservoirs 327 , 328 , and 329 via three fluid routing channels 337 , 338 , and 339 respectively.
- Three fluid filters 340 , 341 , and 342 are mounted within the fluid reservoirs 327 , 328 , and 329 , respectively.
- These filters are preferably constructed from stainless steel wire mesh of a desired porosity to provide good filtration of solid particles and air bubbles when fluid passes from the three fluid reservoirs 327 , 328 , and 329 into the three fluid routing channels 337 , 338 , and 339 .
- a firing chamber layer 344 that defines the volume around each fluid ejector. Attached to the firing chamber layer 344 is a nozzle layer 326 that contains three groups of nozzles 324 , 324 ′ and 324 ′′. The fluid will flow from the three fluid reservoirs 327 , 328 , and 329 through the three fluid filters 340 , 341 , and 342 into the three fluid output ports 337 , 338 , and 339 through the substrate 336 .
- a firing chamber layer 344 includes fluid channels (not shown) and a firing chamber (not shown) formed into the layer that feeds fluid to the ejectors 346 , 346 ′ and 346 ′′.
- the ejectors 346 , 346 ′ and 346 ′′ initiate the ejection of fluid out of the fluid ejection cartridge 302 through the three groups of nozzles 324 , 324 ′ and 324 ′′.
- each group of nozzles is in a column and more preferably in staggered columns, however other patterns, such as circular patterns can also be utilized.
- This embodiment is particularly advantageous when the user desires a self-contained cartridge or integral replaceable unit containing the medicament, the ingestible ink, and a protective coating that is dispensed over the dispensed medicament.
- This embodiment is also advantageous when the user has three compatible medicaments that can be dispensed on the same sheet.
- the properties of the ingestible sheets used in accordance with the present invention depend both on the particular medicament being dispensed and on the particular materials utilized in the sheet, it is generally preferable that the sheets are safely edible or ingestible, and do not have an objectionable “feel” in the mouth.
- the sheets preferably dissolve or degrade in body fluids and/or enzymes.
- the sheets can be made of non-degradable materials that are readily eliminated by the body.
- the sheets are hydrophilic and readily disintegrate in water and more preferably the dissolution or disintegration of the sheets is enhanced at the pH of the fluids in the stomach or upper intestine.
- ingestible sheets that minimize unintended interactions with the medicament dispensed on the sheets and sheets that minimize the release of any sheet component that would cause unintended interactions with the medicament upon dissolution of the sheet are also desirable.
- ingestible sheet that are desirable are the ability to remain stable over extended periods of time, at elevated temperatures, and at high or low levels of relative humidity.
- the ingestible sheets are generally a poor medium for the growth of microorganisms to reduce spoilage.
- ingestible sheets that possess reasonable mechanical properties such as tensile strength and tear strength are desirable to allow the sheets to be processed through the various steps of fabrication of the final dosage form using methods such as are recognized in the art.
- Ingestible sheets that can be utilized in the present invention can be one or a mixture of organic film formers generally classified into two broad categories, i.e. polymeric and paper.
- film formers are starch (i.e. both natural and chemically modified) and glycerin based sheets with or without a releasable backing.
- Other examples include, proteins such as gelatin, cellulose derivatives such as hydroxypropylmethylcellulose and the like; other polysaccharides such as pectin, xanthan gum, guar gum, algin and the like; synthetic polymers such as polyvinyl alcohol, polyvinylpyrrolidone and the like.
- ingestible sheets or edible films that can be utilized are those that are based on milk proteins, rice paper, potato wafer sheets, and films made from restructured fruits and vegetables.
- sheets or films made from restructured fruits and vegetables are advantageous were it is desirable to mask or modify the taste or smell of the medicament being delivered.
- these restructured fruit and vegetable films also provide a convenient approach to encourage children to take various medications as well as providing a more pleasing and varied taste for various medications taken by adults.
- Dispensing the medicament on an ingestible sheet containing a water-expandable foam is preferable for those applications desiring rapid release of the medicament once ingested.
- examples of such materials are an oxidized regenerated cellulose commercially available from Johnson and Johnson under the trademark SURGICEL®, and a porcine derived gelatin powder commercially available from Pharmacia Corporation under the trademark GELFOAM®.
- the form of the ingestible sheet that can be utilized in the present invention can be any of the forms generally recognized in the art such as those used for paper, cardboard or polymeric films.
- the ingestible sheet or roll preferably is uniform in thickness and in width.
- the thickness of the ingestible sheet will depend on the particular medicament being dispensed, the particular ingestible sheet being utilized, and the particular method of manufacture used; the thickness of the ingestible sheet preferably ranges from about 10 to about 350 microns and more preferably from about 25 to about 100 microns thick.
- the dosage forms produced in accordance with the present invention are eminently suited to span the range of production from individualized doses made in a home or hospital environment to the high speed high volume production in a pharmaceutical manufacturing environment.
- the particular width and length will not only depend on both the particular medicament being dispensed and the particular ingestible sheet being utilized, but more particularly on the particular method of manufacture used.
- the ingestible sheet can be in roll or individual sheet forms with widths varying from approximately one centimeter to several meters, and lengths from a few centimeters to several thousand meters, although other lengths and widths can also be utilized.
- an ingestible sheet 404 is in the form of a roll that contains perforations 447 that delineates each dosage form 405 and 405 ′.
- a medicament is dispensed preferably in a two-dimensional array, although other patterns can also be utilized, onto a first portion of the ingestible sheet 404 .
- a sheet advancer (not shown) then advances the ingestible sheet 404 and a second two dimensional array or alternate pattern is dispensed on a second portion of the ingestible sheet.
- the first and second portions form dosage forms 405 and 405 ′ respectively.
- the user or system separates the dosage form 405 from the dosage form 405 ′ by tearing, by cutting along the perforations 447 , or by punching out the dispensed areas of the sheet.
- the user or system can also separate the dosage form 405 from the dosage form 405 ′ before dispensing of the medicament.
- This embodiment is particularly advantageous for systems such as those that have fixed fluid ejection cartridges; however, it can also be utilized in other systems as well.
- the ejector head is approximately the width of the ingestible sheet 404 and the platen (not shown) moves the ingestible sheet in the direction of arrow 448 allowing both the dispensed dose of medicament as well as the appropriate characters or symbols utilizing the ingestible ink to be formed.
- an ingestible sheet 504 is in the form of a sheet with a plurality of dosage forms 505 where each dosage form 505 contains dosage form separators 547 around its peripheral edge.
- the user or system separates the dosage form 505 from the dosage forms 505 ′ and 505 ′′ by bending or, by pushing up in the center of the dosage form 505 , or some other convenient method and peeling the dosage form 505 from a releasable backing 549 shown in FIG. 5 b .
- This embodiment is particularly advantageous for systems used to dispense custom pharmaceutical doses at home, in a hospital or a pharmacy; however, it can also be utilized in other systems as well.
- FIG. 5 a shows the ingestible sheet 504 utilizing dosage form separators 547
- the ingestible sheet 504 can utilize any convenient means of separation such as perforations shown in FIG. 4 .
- FIG. 6 a An embodiment of a method for generating a dosage form where the medicament is dispensed onto the ingestible sheet is shown in a cross-sectional view in FIG. 6 a .
- a drop-firing controller in a fluid dispensing system activates one and, typically, a plurality of fluid ejectors, of a fluid ejection cartridge (not shown), to eject fluid drops 650 , 650 ′, and 650 ′′ of the medicament onto an ingestible sheet 604 forming deposits 651 , 651 ′, and 651 ′′, respectively.
- the fluid drops 650 , 650 ′, and 650 ′′ are shown as being deposited on the surface of the ingestible sheet 604 .
- the ingestible sheet 604 will be a porous and absorbing material which will allow the medicament to be absorbed into the interior of the ingestible sheet 604 .
- a dosage form 605 is generated when the required number of fluid drops of the medicament, to create the desired pharmaceutical dose, have been dispensed on a portion of the ingestible sheet 604 .
- the dosage form 605 contains a two-dimensional array of the deposits 651 , 651 ′ and 651 ′′ of the medicament on the ingestible sheet 604 .
- other arrangements can also be utilized, such as overlapping deposits forming a layer, or a different geometrical arrangement of the deposits 651 , 651 ′, and 651 ′′.
- FIG. 6 b An alternate embodiment of the present invention where the process used for generating a dosage form includes a barrier material deposited over the medicament is shown in a cross-sectional view in FIG. 6 b .
- the drop-firing controller activates one and, typically, a plurality of fluid or barrier ejectors, to eject fluid drops of a barrier material over the deposits 651 , 651 ′, and 651 ′′ of the medicament to form barrier deposits 652 , 652 ′′, and 652 ′′.
- the barrier deposits 652 , 652 ′, and 652 ′′ and deposits 651 , 651 ′, and 651 ′′ of the medicament on the ingestible sheet 604 form dosage form 606 .
- the barrier material acts to seal the medicament from the environment.
- the barrier material provides various protective properties, such as humidity protection, protection from oxidation, inactivation, or contamination.
- the barrier material is an edible coating made from a suitable polymeric material such as a water-soluble polyoxyethylene or cellulose ether derivative.
- the barrier material is an inert material, which will not interact with the deposited medicament. Further, the barrier material may also act as an adhesive as will be discussed later.
- the fluid ejectors activated by the drop-firing controller are either, a different subgroup of fluid ejectors on the fluid ejection cartridge used to dispense the medicament, or a different fluid ejection cartridge.
- FIG. 6 c An alternate embodiment of the present invention where the process used for generating a dosage form includes ingestible ink deposited over the medicament is shown in a cross-sectional view in FIG. 6 c .
- the drop-firing controller activates one and, typically, a plurality of ink ejectors, to eject fluid drops of an ingestible ink at various locations on the ingestible sheet 604 to form dots 654 , 654 ′ and 654 ′′.
- the dots 654 , 654 ′ and 654 ′′ are deposited in patterns using dot matrix manipulation or other means to generate an image, alphanumeric characters, or a machine understood code such as a one or two dimensional bar code, on the ingestible sheet 604 .
- the dots 654 , 654 ′ and 654 ′′, the barrier deposits 652 , 652 ′′, and 652 ′′ and deposits 651 , 651 ′, and 651 ′′ of the medicament on the ingestible sheet 604 form dosage form 607 .
- FIG. 6 d An alternate embodiment of the present invention where the process used for generating a dosage form includes deposition of more than one medicament onto the ingestible sheet 604 ′ is shown in a cross-sectional view in FIG. 6 d .
- the deposits 651 , 651 ′, and 651 ′′ of the medicament and the deposits 652 , 652 ′ and 652 ′′ of the barrier material have been formed on the ingestible sheet 604 ′ as described above.
- the drop-firing controller activates one and, typically, a plurality of fluid ejectors, to eject fluid drops of a second medicament on the ingestible sheet 604 ′ to form deposits 656 , 656 ′ and 656 ′′.
- the fluid ejectors activated by the drop-firing controller to eject the second medicament are either, a different subgroup of fluid ejectors on the fluid ejection cartridge used to dispense the first medicament, or a different fluid ejection cartridge.
- a second barrier is then formed over the deposits 656 , 656 ′ and 656 ′′ forming barrier deposits 658 , 658 ′ and 658 ′′ forming dosage form 608 .
- the second barrier material is the same as the first, however, depending on the properties and compatibilities of the first and second medicaments as well as the first barrier material the second barrier material may be different from the first barrier material.
- FIG. 6 d depicts two different medicaments deposited on the ingestible sheet, more than two medicaments can be deposited on an ingestible sheet.
- FIGS. 6 a - 6 d depict isolated deposits of the medicament and barrier material being deposited onto the ingestible sheet; however, by depositing overlapping deposits of, either or both, the medicament and barrier material layers of each material can be formed.
- the order of deposition can also be varied depending on the particular application.
- the ingestible ink can be deposited before the medicament and the barrier material.
- the ingestible sheet 604 or 604 ′ shown in FIGS. 6 a - 6 d can have, either or both, a releasable backing (not shown) or barrier material (not shown) coated on the surface opposite to the surface on which the medicament is dispensed.
- FIG. 7 a An alternate embodiment of the present invention of a process for manufacturing a dosage form containing more than one medicament is shown in a perspective view in FIG. 7 a .
- multiple ingestible sheets 704 , 706 , and 707 each having multiple portions 760 , 761 , 762 respectively that have a medicament deposited thereon.
- the center ingestible sheet 704 is then sandwiched between the outer sheets 706 and 707 to form a laminated structure 764 where each of the multiple portions 760 , 761 , 762 are positioned where the portion 761 is above the portion 760 which is above the portion 762 .
- This arrangement forms a dosage form 705 that contains multiple medicaments.
- FIG. 7 a depicts three layers of ingestible sheet being laminated
- laminated structures containing two or more layers can be utilized.
- the ingestible sheets 704 , 706 , and 707 can be formed from the same or different materials.
- the various processes and resultant structures depicted in FIGS. 6 a - 6 b can also be utilized.
- other films such as a barrier film or ingestible adhesive film can also be laminated or coated on the different ingestible sheets 704 , 706 , and 707 to improve various properties such as water vapor transmission rate or adhesion depending on the particular medicaments and the particular ingestible sheets being utilized.
- the laminated structure 764 can further be encapsulated and unitized to form single dose 766 as shown in perspective view in FIG. 7 b.
- FIG. 7 c An alternate embodiment of the present invention of a process for manufacturing a dosage form containing more than one medicament is shown in a plan view in FIG. 7 c .
- an ingestible sheet 704 ′ contains multiple portions 760 ′, 761 ′, 762 ′, and 763 each containing a different medicament deposited thereon.
- the four multiple portions form a dosage form 705 ′ that contains multiple medicaments.
- FIG. 7 c depicts four multiple portions, the ingestible sheet 704 ′ containing two or more multiple portions can be utilized.
- the various processes and resultant structures depicted in FIGS. 6 a - 6 b can also be utilized in this embodiment.
- a barrier film or ingestible adhesive film can also be laminated or coated on the ingestible sheet 704 ′ to improve various properties such as water vapor transmission rate, acid resistance, or drug release rate depending on the particular medicaments and the particular ingestible sheet being utilized.
- the multiple portions 760 ′, 761 ′, 762 ′ and 763 can also be utilized in the laminated structure 764 shown in FIG. 7 a by either making a larger dosage form or by folding.
- an expandable foam may be desirable for the rapid release of a medicament once ingested, however, some applications may want to vary the amount of the medicament released over time.
- An advantage of the present invention is the ability to make dosage forms that can vary the amount of medicament or drug released over time as shown in FIGS. 8 a - 8 c .
- a fluid ejection cartridge (not shown) containing at least a medicament ejects the medicament onto an ingestible sheet 804 to form deposits 808 of the medicament dispensed in a two dimensional array over the surface of the ingestible sheet 804 .
- a dosage form 805 contains a first edge 806 having a greater density of the deposits 808 than a second edge 807 where the density of the deposits 808 between the first edge 806 and second edge 807 varies, forming a gradient of the medicament dispensed on the ingestible sheet.
- the medicament is dispensed in the form of deposits 808 over the entire surface of dosage form 805
- other forms can also be utilized such as centering the two dimensional array of deposits 808 in a narrower strip in the center of the dosage form 805 running from the edge 806 to the edge 807 .
- the dosage form 805 is wound into a coil, where the edge 806 having the higher dot density forms the edge contained in the center of the coil and the edge 807 having the lower dot density forms the outer edge of the coil.
- the amount of medicament released can be varied or maintained constant.
- a gradient that increases as the surface area decreases can be used to maintain a constant or increasing release rate depending on the particular gradient used.
- the medicament is deposited in a gradient adapted to provide a dosage form that, after being ingested, the amount of the medicament released increases over time.
- the medicament can also be deposited in a gradient adapted to provide a dosage form that, after being ingested, the amount of the medicament released remains constant over time
- a dosage form 805 ′ that is coiled in the opposite direction where the edge 807 , having the lower dot density, forms the center of the coil and the edge 806 , having the higher dot density, forms the exterior surface of the coil; generates a gradient that decreases as the surface area decreases.
- a dosage form can be used to decrease the release rate as a function of time creating a loading dose.
- the medicament is deposited in a gradient adapted to provide a dosage form that, after being ingested, the amount of the medicament released decreases over time.
- FIG. 8 c A perspective view of an alternate embodiment of the present invention where repeat dosages are formed is shown in FIG. 8 c .
- a fluid ejection cartridge (not shown) containing at least one medicament ejects the medicament onto the ingestible sheet 804 to form the deposits 808 of the medicament dispensed in a two dimensional array over discrete portions 809 on the surface of the ingestible sheet 804 .
- the dosage form 805 ′′ is wound into a coil where each of the discrete portions 809 will release the deposited medicament at different times depending on the thickness of the ingestible sheet 804 , the rate of dissolution of the ingestible sheet 804 and the particular placement of each discrete portion 809 among other variables.
- This embodiment provides a dosage form where a discrete amount of the medicament is released at either repeatable times or discrete amounts of the medicament is released at different times.
- FIGS. 8 a - 8 c are described in terms of fixed dot size and varying the dot density, other methods can also be utilized such as varying the drop size and keeping the dot density constant.
- This ability to vary the dosage release rate over time is an advantage over a conventionally formed tablet, which would release less medicament as the diameter of the tablet decreases.
- the present disclosure allows for a dosage form where the amount of medicament released over time, increases, decreases, remains constant, is repeatable, or a discrete dose is released at different times.
- FIGS. 9 a - 9 b an alternate embodiment of the present invention is shown where the dosage form 905 contains user information 970 to be conveyed to the user or patient.
- FIG. 9 a depicts the user information 970 as a clock showing the time the dose is to be taken or administered.
- the user information 970 is deposited over the two dimensional array of the deposits 908 of the medicament.
- the medicament can also be deposited over the user information.
- FIG. 9 b where the information is a message indicating the name, date, and time to take the medicament.
- the user information 970 can be any symbol, icon, image, or text or combinations thereof, such as a company logo or cartoon character.
- Other examples of the type of information that can be conveyed to the user are the name of the medicament, the expiration date, the flavor of the ingestible sheet, or information having some marketing value.
- the dosage form 905 can also contain manufacturing information 972 to be used by the manufacturer and/or distributor.
- FIG. 9 b depicts the manufacturing information 972 as a two-dimensional bar code.
- the manufacturing information 972 can be any symbol, icon, image, or text or combinations thereof. Examples of various forms are a one-dimensional bar code, a text message, a code, or hologram. Examples of the various types of information that can be utilized in the manufacturing information 972 would be the composition of the ingestible sheet or results of quality control testing, data on compatibility with medicaments, expiration dates, or part tracking information.
- FIG. 10 b A cross-sectional view of an alternate embodiment of the present invention where a dosage form 1005 is encapsulated in a tablet 1079 is shown in FIG. 10 b .
- a lower die chamber 1074 and an upper die chamber 1076 are substantially filled with an excipient powder 1078 as shown in FIG. 10 a .
- Dosage form 1005 which contains the medicament deposited on an ingestible sheet 1004 , is positioned between the two die chambers such that the excipient powder formulation encases or encloses the dosage form 1005 .
- Compressing the lower die chamber 1074 against the upper die chamber 1076 forms the tablet 1079 .
- the tablet is cylindrical with convex outer surfaces typically about 5 to 15 mm. in diameter and about 5 mm.
- the excipient formulation may be similar to the ingestible sheet 1004 or one may select excipients that are dissimilar to the ingestible sheet to obtain tabletting or pharmacokinetic characteristics unlike the ingestible sheet 1004 .
- microcrystalline sugar 97% sucrose and 3% maltodextrin
- cellulose, calcium phosphate, and sodium carboxymethylcellulose can be used with a cellulosic-based ingestible sheet.
- Sugars and corn, wheat, or rice starches can be used with starch-based ingestible sheets.
- silica added to improve flowability, stearates for lubrication, and guar gum or gelatin as binders are examples of dissimilar materials.
- a preferable excipient formulation for direct compression tabletting of a dosage form made from an ingestible sheet which does not include the weight of the ingestible sheet nor the weight of the medicament dispensed is: about 70 weight percent lactose, about 25 weight percent microcrystalline cellulose, about 2 weight percent di-calcium phosphate dihydrate, 2 weight percent sodium carboxymethylcellulose, about 0.3 weight percent fumed silica and about 0.5 weight percent magnesium stearate.
- excipient ranges in formulations for direct compression tabletting of a dosage form made from an ingestible sheet which does not include the weight of the ingestible sheet nor the weight of the medicament dispensed are 0 to about 80 weight percent sugar, 0 to about 25 weight percent microcyrstalline cellulose, 0 to about 90 weight percent calcium phosphate, about 5 to about 25 weight percent starch, about 1 to about 2 weight percent sodium carboxymethylcellulose, about 0.2 to about 0.3 weight percent silica and about 0.5 to about 1 weight percent magnesium stearate can also be utilized.
- the excipient formulation can be modified by adding natural or synthetic polymers such as proteins, carboxymethylcellulose, polyvinylacetate, gelatins, or dextrins can be utilized to improve the adhesive properties of the excipient powder.
- natural or synthetic polymers such as proteins, carboxymethylcellulose, polyvinylacetate, gelatins, or dextrins can be utilized to improve the adhesive properties of the excipient powder.
- an ingestible adhesive can be dispensed between the two die chambers prior to applying pressure to form the tablet.
- a monomeric methyl or ethylcyanoacrylate type adhesive can be utilized.
- the ingestible sheet 1004 of the dosage form 1005 can be perforated to allow greater contact area between excipient powder 1078 contained in the upper die chamber 1076 and the lower die chamber 1074 or the dosage form 1005 can be formed in the shape of a ring containing an area in the center of the dosage form 1005 that allows the excipient powder in the two chambers to bond.
- FIG. 11 An exemplary system 1100 for the interactive dispensing of a medicament on an ingestible sheet is shown as a schematic diagram in FIG. 11 .
- a processor 1180 is coupled to a drop-firing controller via dispense interface 1182 .
- the processor 1180 converts a specified quantity of the medicament to be dispensed into a number of drops or ejections to be activated by the drop-firing controller. This number is transmitted via the dispense interface 1182 to the drop-firing controller of the medicament dispensing system 200 .
- the specified quantity of the medicament is then ejected onto the ingestible sheet forming a dosage form.
- the system 1100 also includes a storage device 1186 and a display device 1184 coupled to the processor 1180 to store and display information. For example user input information, system parameters, information and parameters associated the ingestible sheet can all be stored on storage device 1186 and/or displayed on display device 1184 .
- the system 1100 having the processor 1180 , display device 1184 , and storage device 1186 is advantageous over current methods of forming pharmaceutical doses in that it allows a user such as a doctor or pharmacist to generate variable doses as well as custom doses in the convenience of a hospital, pharmacy, or home environment. Further, such a system can also be utilized as a point of sale machine, in such locations as a pharmacy or a supermarket, to allow customers to create variable or custom doses of vitamins, nutritional supplements, or other over-the-counter medications.
- the system 1100 also includes a user interface 1188 or signal receiver that is coupled to the processor 1180 and is also coupled via communication channel 1193 to an external communication network 1190 as shown in FIG. 11 .
- the external communication 1190 is a digital network such as what is commonly referred to as the Internet.
- Other communication channels such as wireless communication, wireline telephone, digital cable television, as well as other point-to-point, point-to-multipoint, and broadcast communications methods can also be used.
- the user interface or signal receiver 1188 receives a signal from a remote signal source specifying information to be utilized by system 1100 .
- the remote signal source can specify the quantity of medicament to be dispensed or an authorization code verifying the authority of the user to dispense the medicament.
- the system 1100 can also be coupled to a provider system 1192 via network 1190 .
- the provider system 1192 includes a provider processor 1181 , coupled to a provider display 1185 , a provider storage device 1187 , and a provider interface 1189 .
- the provider interface 1189 is coupled via provider channel 1194 to the external communication network 1190 .
- the provider system 1192 is utilized, for example, by a health care provider such as a doctor, a pharmacist, a nurse, appropriate insurance personnel, or other appropriate health care professional.
- FIG. 11 shows a single provider coupled to the system 1100 it also preferable to have multiple providers, such as doctors, pharmacists, nurses, insurance providers, and pharmaceutical manufacturers all coupled to the system 1100 over the external network 1190 .
- system 1100 is located in a home where the patient can request information on the medicament and appropriate dosage information from a pharmacist, request information on the ingestible sheet from the manufacturer, and current health information from a doctor or nurse over the network; to form the appropriate pharmaceutical dose for that time or multiple doses to cover a period of the next day to several days or weeks.
- a system also allows potentially adverse drug interactions and individual allergies or intolerances and sensitivities to be flagged.
- FIGS. 12-13 An exemplary embodiment of an interactive method for generating a dosage form where the medicament is dispensed onto the ingestible sheet is shown as flow diagrams in FIGS. 12-13 .
- An overview of the method is shown in FIG. 12 .
- the various materials such as the medicament and the ingestible sheet are loaded or inserted into a medicament dispensing system.
- information indicative of the materials is read either by the system or by a user who then manually enters the information into the system, such as the composition of the ingestible sheet and the active ingredients of the medicament.
- various forms of information are requested by the system such as requesting from the doctor or pharmacist the quantity or dose of the medicament to be dispensed.
- step 1230 various forms of information are specified and then transmitted and received by the system, such as the doctor or pharmacist specifying the quantity or dose of the medicament to be dispensed.
- Various forms of information are verified in step 1240 such as verifying that the dose is within the correct range.
- the medicaments as well as other materials such as the barrier material are dispensed on the ingestible sheet in step 1250 providing all of verification steps were successfully completed.
- step 1260 appropriate user and manufacturing information is printed on the ingestible sheet.
- FIG. 13 a A more detailed view of the various steps associated with the loading step 1200 is shown in FIG. 13 a .
- an off-axis medicament container is inserted into the dispensing system where the container, after insertion is fluidically coupled to a medicament reservoir of a semi-permanent cartridge.
- Either a replaceable or semi-permanent medicament ejection cartridge is inserted in the dispensing system in step 1302 .
- An off-axis ingestible ink container, and either a replaceable or semi-permanent ingestible ink ejection cartridge, are inserted into the dispensing system in steps 1303 and 1304 respectively, where the off-axis ink container is fluidically coupled to an ink reservoir in a semi-permanent ink cartridge.
- a cartridge containing a mixture of the medicament and the ingestible ink can be inserted into the system in step 1305 .
- an ingestible sheet is loaded into the dispensing system.
- step 1311 information is read from the ingestible sheet.
- the composition or the expiration date of the ingestible sheet can be read by the system utilizing an image acquisition system scanning a bar code.
- this information is stored in a machine readable form, however, a human perceptible form can also be utilized.
- steps 1312 and 1314 information from the medicament cartridge and from the medicament container is accessed or read respectively.
- this information is stored in a memory chip that this accessed, however, other means can also be utilized such as printing the information on the cartridge in a machine readable or human perceptible form.
- step 1321 the quantity of the medicament to be dispensed is requested by the medicament dispensing system. For example, this could be displayed on a display device located in the vicinity of the dispensing system or it can be displayed on a remote display device such a doctor's or pharmacist's office.
- User information is requested by the system in step 1322 . This information is any information about the user, i.e. typically the patient, that can be utilized for example in determining the appropriate dose, such as the patient's height, weight, age, etc. or information that is used by the user in administering the dosage form.
- step 1324 manufacturer's information is requested by the system. This information is any information from the manufacturer of the medicament and/or the ingestible sheet. For example, this information can be the same or similar to that obtained in steps 1311 , 1312 , 1314 and can be used in conjunction with that information to act as a verification.
- step 1331 the quantity of the medicament to be dispensed is specified, for example by a doctor or pharmacist, transmitted to and received by the medicament dispensing system.
- dosage information such as dosage forms that vary the amount of medicament released over time as shown in FIG. 8 , is specified, transmitted to and received by the system.
- User information is specified transmitted to and received by the system in step 1334 . This information is any information about the user, i.e. typically the patient, that can be utilized for example in determining the appropriate dose, such as the patient's height, weight, age, etc. or information that is used by the user in administering the dosage form.
- step 1336 manufacturer's information is specified.
- This information is any information from the manufacturer of the medicament and/or the ingestible sheet.
- this information can be the same or similar to that obtained in steps 1311 , 1312 , 1314 and can be used in conjunction with that information to act as a verification.
- step 1341 the dosage quantity is verified.
- step 1341 verifies information obtained in a previous step such as step 1331 or multiple steps is used to verify the dosage specified, is either correct or within an acceptable range.
- the information accessed from the medicament cartridge in step 1312 is compared to the specified quantity to be dispensed in step 1331 .
- Another example would be the use of a third party authorization key where the dosage quantity is verified utilizing the key that is located on the user's system or is accessed via a network such as the Internet.
- the dosage information specified in step 1332 is verified in step 1342 .
- step 1332 the information specified in step 1332 can be verified from stored information stored on a storage device. However, if step 1332 is being performed for the first time with a given user then either the information can be retransmitted back to the person specifying or the information can be verified by a third party such as a doctor or an insurance agent via a network such as the Internet.
- step 1344 user information is verified. This step can also be carried out using either previously stored information or a third party as described above in step 1342 .
- the manufacturer's information is verified in step 1346 . This step can also be carried out using either previously stored information or a third party as described above in step 1342 .
- the manufacturer's information is any information from the manufacturer of the medicament or the ingestible sheet obtained in steps 1336 or step 1210 .
- step 1351 the quantity of medicament to be dispensed is converted on a processor into a number of activations of a fluid ejector.
- the ingestible sheet is advanced into a fluid ejection area beneath the ejector head or heads in step 1352 .
- the dosing data preferably in the form of the number of activations of a fluid ejector is transmitted from the processor to the dispense system in step 1354 .
- the fluid ejectors are activated to produce the pharmaceutical dose.
- the drops are ejected in a predetermined fluid swath pattern using dot matrix manipulation, forming the pharmaceutical dose from the cartridge containing the medicament, however other processes of firing the fluid ejectors can also be utilized.
- a custom medicament dose can also be generated by inputting the user information, the manufacturing information, dosage information, as well as appropriate information from the medicament cartridge into a dose algorithm. The dose algorithm then combines this information in a predetermined manner to generate a custom medicament dose.
- step 1260 A more detailed view of the various steps associated with printing information on the ingestible sheet, in step 1260 , is shown as a flow diagram in FIG. 13 g .
- appropriate manufacturing information such as the composition of the ingestible sheet and the name or the medicament, is printed on the ingestible sheet.
- the manufacturing information printed in step 1361 can be printed either in a machine understood form in step 1363 or it can be printed in a human perceptible form in step 1362 or in some combination thereof.
- the user information such as the name of the user or patient and the date and time for administering the dosage form, is printed on the ingestible sheet in step 1364 .
- the barrier material is dispensed over the medicament previously dispensed in step 1356 .
- the barrier material may be dispensed before the medicament is dispensed.
- the present invention can advantageously reduce the number of therapeutically inactive materials, the number of dilutions, and the number of mixings in the manufacture of unit dosage forms.
- the medicament cartridge and the medicament dispensing system of the present invention provides for the custom dispensing of pharmaceutical unit dosage forms where the type of pharmaceutical and the quantity of the selected drug can be easily varied to meet a specific prescription.
- the medicament cartridge and the medicament dispensing system of the present invention provides the ability of dispensing multiple, different pharmaceuticals in varied, selected quantities to a single receiving medium thus simplifying the taking of drugs, especially combinations of different drugs by providing multiple drugs in one dose.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Primary Health Care (AREA)
- Medical Informatics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
A method of applying an orally-ingestible medicament to an orally-ingestible carrier comprising the steps of controlling a relative position between a fluid ejector and the carrier, and ejecting a plurality of drops of solution onto the carrier, wherein the plurality of drops includes a desired therapeutic quantity of the orally-ingestible medicament.
Description
- This application is a continuation-in-part of U.S. application Ser. No. 10/028,450, filed Oct. 24, 2001.
- 1. Field of the Invention
- The present disclosure relates to fluid-jet medicament delivery. More particularly, the present disclosure relates to applying precise doses of medicament onto an edible sheet using fluid-jet technology.
- 2. Description of the Art
- Oral administration of pharmaceuticals is one of the most widely used methods to provide effective therapy for a variety of illnesses. Many powdered medications are typically administered orally to a person in a dosage form such as tablets or capsules, while still others are in liquid form. The release of orally administered medications falls into two broad categories, buccal or sublingual administration, and oral dissolution. For example, enteric coated tablets that release the medication in the intestinal tract of the patient. Further, many individuals suffer from chronic health problems that require the regular administration of medicaments. Diseases such as diabetes, allergies, epilepsy, heart problems, AIDS, and even cancer requires the regular delivery of precise doses of medicaments if patients are to survive over long periods of time. Such chronic treatment creates the need to regularly obtain additional medication. This can be extremely troublesome for those patients that lack the mobility to easily travel to a pharmacist to refill medications, such as the elderly and infirm. Thus, a method and a dosage form that provides the ability to make custom doses, outside of the large pharmaceutical manufacturing plants, is desirable.
- Most pharmaceuticals involve dosage units in the microgram to milligram range of the purified active ingredient or ingredients. Thus, many pharmaceutical doses in tablet or liquid form are made in formulations of a predetermined quantity of pharmaceutical units in each dose. Such pharmaceutical doses are frequently available in fixed different strengths, such as 50 mg, 100 mg, etc.
- Unfortunately, such conventional oral dosage forms suffer from a number of disadvantages. Typically, to effectively handle and dispense small doses a considerable amount of adjuvant material must be added in order that the final dosage form is of a manageable size. Thus, typical methods for manufacturing include the mixing of the pure drug with various other substances commonly referred to as excipients or diluents that are therapeutically inert and acceptable by regulatory bodies, such as the FDA. Excipients may also protect the drug from deterioration by oxidation, humidity, and light. Palatability can be improved through the addition of flavorants and identification by use of colorants. This mixing process often requires the use of sophisticated, complex expensive machinery. Certain excipients may be needed to improve the flowability of the drug and diluents through the mixing machinery. Therefore, a method and dosage form that reduces the mixing of the active drug with other substances, and utilizes less complex and expensive machinery would also be desirable.
- These therapeutically inactive or inert materials also have the disadvantage that each such material must be evaluated before use in terms of potential incompatibilities with the medicaments present. For example, some of these materials, such as lubricants or disintegrants, may present problems concerning the bioavailability of the active ingredient. Further, the certification of new drugs is a lengthy and costly process involving animal studies followed by chemical trials to establish both the efficacy and safety of the new drug. Because a pharmaceutical's characteristics may be affected by changes in manufacturing and/or packaging, the approval process limits the approval to a particular manufacturing and packaging process. Thus, the ability to rapidly and easily change dosage units is extremely limited in conventional pharmaceutical manufacturing processes.
- Drugs with a narrow therapeutic range must also be precisely dosed. If the patient falls below the range, the desired effect will not occur. However, if the patient is above the range then the risk of toxic effects increases. Clinicians assume the dose units manufactured are uniform and that generic equivalents have equal bioavailability. The many FDA generic formulation rejections and recalls for pharmaceuticals that have too high or low of a drug level, however, are evidence that accuracy and precision are still challenges for pharmaceutical manufacturing.
- The ability to easily make a custom dose using tablets or capsules utilizing current technology is also difficult. It is virtually impossible to split or divide a capsule to decrease the dose administered requiring that the smallest dose be predetermined. Further, in the case of tablets a patient or pharmacist may often encounter difficulty in splitting or dividing even relatively large tablets that have a notch or groove at a predetermined breaking point to form a lower dosage unit. The splitting or breaking often results in fragments of unequal size. Thus, a method and dosage form that allows for variable doses to be formed outside the pharmaceutical manufacturing plant is desirable.
-
FIG. 1 a is a perspective view of a fluid cartridge containing an orally-ingestible medicament; -
FIG. 1 b is a perspective view of fluid ejection cartridges held within a carriage; -
FIG. 1 c is a perspective view of fluid ejection cartridges and an image acquisition system held within a carriage; -
FIG. 2 a is a perspective view of a orally-ingestible medicament dispensing system; -
FIG. 2 b is a perspective view of a orally-ingestible medicament dispensing system with an ingestible sheet tray; -
FIG. 3 is a cross-sectional view of a fluid ejection cartridge; -
FIG. 4 a perspective view of an ingestible sheet; -
FIG. 5 a is a plan view of an ingestible sheet; -
FIG. 5 b is a cross-sectional view of the ingestible sheet shown inFIG. 5 a. -
FIG. 6 a is a cross-sectional view of a method for generating a dosage form; -
FIG. 6 b is a cross-sectional view of a method for generating a dosage form; -
FIG. 6 c is a cross-sectional view of a method for generating a dosage form; -
FIG. 6 d is a cross-sectional view of a method for generating a dosage form; -
FIG. 7 a is a perspective view of a process for manufacturing a dosage form; -
FIG. 7 b is a perspective view of an encapsulated and unitized single dose; -
FIG. 7 c is a plan view of a process for manufacturing a dosage form; -
FIG. 8 a is a perspective view of a dosage form to vary the amount of the medicament released over time; -
FIG. 8 b is a perspective view of a dosage form to vary the amount of the medicament released over time; -
FIG. 8 c is a perspective view of a dosage form to vary the amount of the medicament released over time; -
FIG. 9 a is a plan view of a dosage form containing user information; -
FIG. 9 b is a plan view of a dosage form containing user information and manufacturing information; -
FIG. 10 a is a cross-sectional view of a process for manufacturing a dosage form; -
FIG. 10 b is a cross-sectional view of a dosage form manufactured using the process shown inFIG. 10 a; -
FIG. 11 is a block diagram of a medicament dispensing system for the interactive dispensing of a medicament on an ingestible sheet; -
FIG. 12 is a flow diagram of an interactive method for generating a dosage form; -
FIG. 13 a is a flow diagram showing a more detailed view of the steps for loading materials shown inFIG. 12 ; -
FIG. 13 b is a flow diagram showing a more detailed view of the steps for reading information from materials shown inFIG. 12 ; -
FIG. 13 c is a flow diagram showing a more detailed view of the steps for requesting information shown inFIG. 12 ; -
FIG. 13 d is a flow diagram showing a more detailed view of the steps for specifying information shown inFIG. 12 ; -
FIG. 13 e is a flow diagram showing a more detailed view of the steps for verifying information shown inFIG. 12 ; -
FIG. 13 f is a flow diagram showing a more detailed view of the steps for applying the medicament on the ingestible sheet shown inFIG. 12 ; -
FIG. 13 g is a flow diagram showing a more detailed view of the steps for printing information shown inFIG. 12 . - The present invention advantageously uses the multi-drop deposition capability of a fluid-jet ejection system to dispense medicaments on an ingestible carrier such as an ingestible sheet. Although one embodiment describes the use of a thermally activated fluid-jet ejection cartridge to dispense medications in the form of drops on an ingestible media, other methods of activating fluid-jet ejection, such as piezoelectric or acoustic activation, may also be used in the present invention. The fluid ejection system of the present disclosure includes a drop-on-demand type fluid dispenser. The present disclosure provides greater control of the drug dose than a typical diluting and mixing apparatus by producing precise and repeatable doses onto an ingestible carrier. Another feature of the present invention is the ability to dispense multiple different pharmaceuticals in varied quantities onto an ingestible carrier.
- For purposes of this description, the term “medicament” shall mean a substance that treats or prevents or alleviates a disease or illness and/or the symptoms of the disease or illness. An example of a medicament is a pharmaceutical substance, such as a drug. The term “medicament” can be used to refer to such a substance in pure form, a mixture of the substance with other substances, and/or a solution including the substance. An “orally-ingestible medicament” is a medicament intended for intake into the digestive track via the mouth, as opposed to a medicament that is intended to be injected or surgically implanted. An orally-ingestible medicament may be configured to be digested and/or otherwise act in one or more of the mouth, throat, stomach, intestines, or any other portion of the alimentary canal.
- Referring to
FIG. 1 a, an exemplary embodiment of afluid ejection cartridge 102 is shown in a perspective view. In this embodiment, afluid reservoir 128, in the body portion of thefluid ejection cartridge 102, typically contains a medicament used to generate the pharmaceutical dose and/or an ingestible ink used to generate an image or characters on an ingestible sheet or other carrier used to make a dosage form. Thefluid reservoir 128 is fluidically coupled, preferably through internal passageways, to a substrate (not shown) that is attached to the back of anozzle layer 126. The substrate (not shown) normally contains an energy-generating element or fluid ejector (not shown) that generates the force necessary for ejecting the fluid held in the reservoir. Two widely used energy generating elements are thermal resistors and piezoelectric elements. The former rapidly heats a component in the fluid above its boiling point causing vaporization of the fluid component resulting in ejection of a drop of the fluid. While the latter utilizes a voltage pulse to generate a compressive force on the fluid resulting in ejection of a drop of the fluid. For more information on various transducers utilized in drop-on-demand fluid ejection cartridges see Stephen F. Pond, Ph.D. Inkjet Technology and Product Development Strategies, ch 4 (Torrey Pines Research, 2000); and more particularly for thermal inkjet technology see J. Stephen Aden et al., The Third-Generation HP Thermal InkJet Printhead, Hewlett-Packard Journal, vol. 45, no. 1, pg. 41-45, February 1994. - The substrate (not shown), the
nozzle layer 126,nozzles 124, and aflexible circuit 125 form what is generally referred to as anejector head 122. In other embodiments theejector head 122 includes the substrate (not shown), thenozzle layer 126 and thenozzles 124. Thenozzle layer 126 contains one ormore nozzles 124 through which fluid, that is contained in a chamber around the fluid ejectors, is ejected by activation of the fluid ejectors (not shown) located in close proximity to thenozzles 124. Each activation of a fluid ejector results in the ejection of a precise quantity of fluid in the form of a fluid drop; thus, the number of activations of the fluid ejector controls the number of drops ejected. For more information on drop formation see for example Jaime H. Bohorquez et al., Laser-Comparable Inkjet Text Printing, Hewlett-Packard Journal, vol. 45, no. 1, pg. 9-17, February 1994; or William A. Buskirk et al., Development of a High Resolution Thermal Inkjet Printhead, Hewlett-Packard Journal, vol. 39, no. 5, pg. 55-61, October 1988. - The
fluid ejection cartridge 102 described in the present invention can reproducibly and reliably eject drops in the range of from about ten femto-liters to about ten micro-liters depending on the parameters of the fluid ejection cartridge such as the size and geometry of the chamber around the fluid ejector, the size and geometry of the fluid ejector, and the size and geometry of the nozzle. Thus, the present invention has the ability to accurately dispense a medicament solution with a part per million to a part per billion accuracy. This is particularly advantageous when dispensing expensive medicaments, such as certain hormones, antibiotics, and medicaments derived from some natural products in scarce supply. The accuracy and precision is advantageous when dispensing concentrated substances with high potency. In addition, a further advantage of utilizing thefluid ejection cartridge 102 of the present invention is a reduction, to less than one percent by weight, in the amount of excess medicament that is dispensed to assure proper label dosage. In other words, medicament can be accurately applied to a carrier in the form of a plurality of closely sized drops, which include substantially equal amounts of medicament. By controlling the number of drops that are applied, the total amount of medicament can be controlled. As used herein, “target dose” shall mean the exact amount of medicament that is to be placed onto a carrier, and “therapeutic quantity” is a range of acceptable doses that includes the target dose. This embodiment is also advantageous for utilizing a mixture of the medicament and an ingestible ink contained in thefluid reservoir 128. -
Fluid ejection cartridge 102, can utilize a method of creating discrete sized drops that are independently ejected from a particular nozzle utilizing a particular fluid ejector while maintaining a narrow drop volume distribution. In addition, the narrow drop volume distribution can be maintained over multiple nozzles each having a separate fluid ejector and fired independently or simultaneously. Such a cartridge can be characterized by a very narrow distribution of drop volumes and may have anywhere from a 2×, 3× or even more narrower drop volume distribution than conventional fluid ejector devices such as hydraulic, air assisted, or ultrasonic nozzles that form a spray of fluid having varying drop sizes. The range in drop volume is generally within 10 percent of the targeted or specified value and under steady state conditions can be within about 6 percent or less of the targeted value. Thus, a medicament can be accurately dispensed with a part per million to a part per billion accuracy. - The
nozzle layer 126 may be formed of metal, polymer, glass, or other suitable material such as ceramic. Preferably, thenozzle layer 126 is formed from a polymer such as polyimide, polyester, polyethylene naphthalate (PEN), epoxy, or polycarbonate. In an alternate embodiment, thenozzle layer 126 is formed from a metal such as a nickel base enclosed by a thin gold, palladium, tantalum, or rhodium layer. Preferably, the components of theejector head 122 and the fluid reservoir are formed of materials that are inert to the medicament and/or the ingestible ink which are to be dispensed therefrom. Thus, inert materials such as glass, ceramic, stainless steel, noble metals, and polymers inert to the medicament are preferred. - The fluid is selectively expelled from the one or more of the
nozzles 124 by electrical signals communicated throughelectrical contacts 130 and associatedconductive traces 132 disposed on theflexible circuit 125. In the preferred embodiment, theflexible circuit 125 is typically bent around an edge of thefluid ejection cartridge 102 and secured. Theelectrical traces 132 are routed from theelectrical contacts 130 to bond pads on the substrate (not shown) to provide electrical connection for thefluid ejection cartridge 102. Thus, by communicating the proper electrical signal through the electrical contacts 130 a fluid ejector is activated the appropriate number of times to eject a predetermined number of drops. - An
information storage element 133 is disposed oncartridge 102. Preferably, theinformation storage element 133 is coupled to a flexible circuit such as theflexible circuit 125 as shown inFIG. 1 a. Theinformation storage element 133 is any type of memory device suitable for storing and outputting information that may be related to properties or parameters of the medicament contained within thefluid reservoir 128. Preferably, theinformation storage element 133 is a memory chip mounted on theflexible circuit 125 and electrically coupled through theelectrical traces 132 to theelectrical contacts 130. Alternatively, theinformation storage element 133 can be encapsulated in its own package with corresponding separate electrical traces and contacts. - When the
fluid ejection cartridge 102 is either inserted into, or utilized in, a dispensing system theinformation storage element 133 is electrically coupled to a controller that communicates with theinformation storage element 133 to use the information or parameters stored therein. However, other forms of information storage can also be utilized for theinformation storage element 133, such as a bar code or other device that allows storage of information. Further, theinformation storage element 133 can be mounted elsewhere on or within the body of thefluid ejection cartridge 102 with appropriate contacts and electrical connections to access the storage element depending on the particular application. In addition, theinformation storage element 133 can also be placed on an off-axis container utilized with semi-permanent ejector heads or cartridges. - The
information storage element 133 may contain information such as the particular medicament or other material contained in thefluid reservoir 128; the quantity of material remaining in thefluid reservoir 128 based on the number of drops dispensed or the number of times the fluid ejector has been activated. Other information can include the date of manufacture, inspection dates, quality control information, dispensing system parameters, and customer/patient information. - The
fluid ejection cartridge 102, or more preferably a set of individualfluid ejection cartridges carriage 111, as illustrated in a perspective view inFIG. 1 b. Alternative embodiments can include one or more semi-permanent ejector heads that are replenished from one or more fluidically-coupled off-axis fluid containers, or a single fluid ejection cartridge having one or more fluids available within the fluid ejection cartridge and fluid ejecting nozzles designated for each fluid integrally coupled with each fluid reservoir, or a single fluid ejection cartridge having a mixture of the medicament and ingestible ink. The present invention can be satisfactorily employed by at least these alternatives. - An alternate embodiment of the present invention where a
carriage 111′ contains animage acquisition system 150 is shown inFIG. 1 c. In this embodiment, theimage acquisition system 150 contains acamera 151 and alight source 152. As thecartridge 102 ejects drops of a medicament onto the ingestible sheet, the drops may exhibit spots on the sheet having various visual or otherwise detectable geometric aspects, such as area extent, shape, and position. Preferably, thelight source 152 is positioned relative to thecamera 151 so that thecamera 151 can image these detectable geometric aspects. Although as depicted inFIG. 1 c thelight source 152 comprises a single source, multiple sources can also be used. Thelight source 152 is preferably a light emitting diode (LED), although other light sources such as light bulbs or lasers can also be utilized. - The
image acquisition system 150 also contains, a camera and light source,controller 153 that is preferably coupled to a drop-firingcontroller 214 as shown inFIG. 2 a. When eitherfluid ejection cartridge controller 214, to dispense medicament or ingestible ink on an ingestible sheet, thecamera controller 153 is correspondingly triggered by the drop-firingcontroller 214; thus activating thecamera 151 to gather image information pertaining to a portion of the surface of an ingestible sheet on which either a medicament or ingestible ink has been deposited. Thecamera 151 as shown inFIG. 1 c can be any camera that can image the desired qualities on an ingestible sheet such as a camera that captures 2 dimensional images or line scan cameras that capture a narrow-stripped portion of the surface being imaged and these narrow-stripped portions are combined to for a complete two dimensional image. - In addition to capturing images of either the medicament or ingestible ink or other material dispensed on the ingestible sheet the
image acquisition system 150 can also be utilized to capture images of information that has been placed on an ingestible sheet prior to deposition of the medicament or ingestible ink. Examples of such information are the composition of the ingestible sheet or results of quality control testing; data on compatibility with the medicaments, i.e. whether the ingestible sheet is compatible or incompatible with medicament being dispensed; patient information such as height, weight, name, age, prescribed dose etc.; expiration dates, temperature and/or humidity sensors, indicating that the ingestible sheet is no longer effective or it has been exposed to an extreme which could hinder its effectiveness. Although theimage acquisition system 150, as depicted inFIG. 1 c, is mounted incarriage 111′, other arrangements can also be utilized such as mounting theimage acquisition system 150 on a separate carriage, or locating the image acquisition system in a different portion of amedicament dispensing system 200 shown inFIG. 2 a. - The essential parts of a
medicament dispensing system 200 according to an embodiment of the present invention is shown in a block diagram inFIG. 2 a. In this embodiment, a platen to which aningestible sheet 204, such as a starch or glycerin based paper, is transported by mechanisms that are known in the art. Thecarriage 111 is typically supported by aslide bar 213 or similar mechanism within thesystem 200 and physically propelled along theslide bar 213 to allow thecarriage 111 to be translationally reciprocated or scanned back and forth across theingestible sheet 204. The scan axis, X, is indicated by an arrow inFIG. 2 a. - Under control of the
drop firing controller 214 and aposition controller 218, thecarriage 111 scans across theingestible sheet 204, and fluid drops are selectively ejected from fluid ejectors disposed within the fluid ejection heads of the set offluid ejection cartridges ingestible sheet 204. The power to activate the fluid ejectors is supplied by apower supply 215. The drops are ejected to form predetermined dot matrix patterns, forming both the pharmaceutical dose from the cartridge containing the medicament, and images or alphanumeric characters from the cartridge containing the ingestible ink. - Rasterization of the data can occur in a host computer such as a personal computer or PC (not shown) prior to the rasterized data being sent, along with the system control commands, to the system, although other system configurations or system architectures for the rasterization of data are possible. This operation is under control of system driver software resident in the system's computer. The system interprets the commands and rasterized data to determine which drop ejectors to fire. An arrow in
FIG. 2 a indicates the fluid drop trajectory axis, Z, directed from thefluid ejection cartridges ingestible sheet 204. When a swath of fluid ejection has been completed, theingestible sheet 204 is moved an appropriate distance along the ingestible sheet axis, Y, indicated by the arrow, in preparation for the next swath. This invention is also applicable to medicament dispensing systems employing alternative means of imparting relative motion between the fluid ejection cartridges and the ingestible sheet, such as those that have fixed fluid ejection cartridges and move the ingestible sheet in one or more directions, and those that have fixed ingestible sheet and move the fluid ejection cartridges in one or more directions. - As can be appreciated from a preferred embodiment shown in
FIG. 2 a, theingestible sheet 204 is advanced into a fluid ejection area beneath the ejector heads 122 and 123 (shown inFIG. 1 b) by a sheet positioning mechanism commonly referred to as a sheet positioner or sheetadvancer including rollers 217, aplaten motor 216, and traction devices (not shown). In a preferred embodiment, thefluid ejection cartridges ingestible sheet 204 on the platen by acarriage motor 212 in the ±X direction, perpendicular to the Y direction of entry of the medium. Theplaten motor 216 and thecarriage motor 212 are typically under the control of the sheet andcartridge position controller 218. An example of such a positioning and control apparatus may be found described in U.S. Pat. No. 5,070,410. Thus, theingestible sheet 204 is positioned in a location so that thefluid ejection cartridges controller 214 of themedicament dispensing system 200. These drops of fluid are expelled from selected orifices in the ejector heads 122, 123 (as shown inFIG. 1 b) in a band parallel to the scan direction as thefluid ejection cartridges ingestible sheet 204 by thecarriage motor 212. Once thefluid ejection cartridges - When the
fluid ejection cartridges ingestible sheet 204, theingestible sheet 204 is conventionally incrementally advanced by theposition controller 218 and theplaten motor 216. Once the fluid ejection cartridges have reached the end of their traverse in the X direction on theslide bar 213 or similar support mechanism, they are either returned back along theslide bar 213 while continuing to eject fluid or returned without ejecting. Theingestible sheet 204 may be advanced by an incremental amount equivalent to the width of the fluid-ejecting portion of the fluid-ejecting head or some fraction thereof related to the spacing between the nozzles. Control of theingestible sheet 204, positioning of the fluid ejection cartridge, and selection of the correct fluid ejectors for creation of both the medicament dose and the image or character written is determined by theposition controller 218 and the drop-firingcontroller 214. The controllers may be implemented in a conventional electronic hardware configuration and provided operating instructions fromconventional memory 219. - The
medicament dispensing system 200 can also contain aheater 221 coupled to aheater controller 220 as shown inFIG. 2 a. Theheater 221 heats theingestible sheet 204 to remove water and other solvents deposited on theingestible sheet 204 after deposition of the medicament or ingestible ink. The heater also contains a temperature sensor (not shown) that is coupled to theheater controller 220 to maintain theingestible sheet 204 at the appropriate temperature. The particular temperature that the temperature sensor maintains depends on the particular medicament or ingestible ink being dispensed, and on the particularingestible sheet 204 being utilized. Although theheater 221 is located above therollers 217 as depicted inFIG. 2 a the heater can also be located in other portions of themedicament dispensing system 200 such as underneath theingestible sheet 204 in front of therollers 217. - A perspective view of an alternate embodiment of the present invention where the
medicament dispensing system 200 includes aningestible sheet tray 299 is shown inFIG. 2 b. In this embodiment, thetray 299 holds separateingestible sheets 204′ that are advanced into the fluid ejection area beneath ejector heads (not shown) byrollers 217′ and other mechanisms as described above inFIG. 2 a. Preferably thetray 299 holds from 1 to about 250 sheets, however, depending on the particular system, ingestible sheet, and medicament being utilized, thetray 299 may hold more than 250 sheets. - The apparatus described above makes unique use of an automated fluid ejecting device, having at least one medicament supply in a reservoir or chamber and at least one, and preferably, a plurality of fluid ejectors in an array, each ejector dispensing a precise volume of fluid in essentially individual droplets on each activation of the fluid ejector. This arrangement enables the quantity of the medicament dispensed to be varied in a specified area of the ingestible sheet thereby enabling either custom, or a wide range of doses to be more easily prepared. The apparatus or system as depicted in
FIGS. 2 a and 2 b may be used in a manufacturing environment, a pharmacy, or even in other dispensing locations such as in a hospital, home etc. to automatically prepare pharmaceutical doses in response to patients needs. - A cross-sectional view of an alternate embodiment of the present invention where a
fluid ejection cartridge 302 includes threefluid reservoirs cartridge body 334 is shown inFIG. 3 . In this embodiment, asubstrate 336 is attached to the outer surface of thecartridge body 334, and includes three groups offluid ejectors fluid reservoirs fluid routing channels fluid filters fluid reservoirs fluid reservoirs fluid routing channels - Attached to the
substrate 336 is afiring chamber layer 344 that defines the volume around each fluid ejector. Attached to thefiring chamber layer 344 is anozzle layer 326 that contains three groups ofnozzles fluid reservoirs fluid filters fluid output ports substrate 336. Afiring chamber layer 344 includes fluid channels (not shown) and a firing chamber (not shown) formed into the layer that feeds fluid to theejectors ejectors fluid ejection cartridge 302 through the three groups ofnozzles - Although the properties of the ingestible sheets used in accordance with the present invention depend both on the particular medicament being dispensed and on the particular materials utilized in the sheet, it is generally preferable that the sheets are safely edible or ingestible, and do not have an objectionable “feel” in the mouth. In addition, the sheets preferably dissolve or degrade in body fluids and/or enzymes. However, the sheets can be made of non-degradable materials that are readily eliminated by the body. Preferably the sheets are hydrophilic and readily disintegrate in water and more preferably the dissolution or disintegration of the sheets is enhanced at the pH of the fluids in the stomach or upper intestine. Further, ingestible sheets that minimize unintended interactions with the medicament dispensed on the sheets and sheets that minimize the release of any sheet component that would cause unintended interactions with the medicament upon dissolution of the sheet, are also desirable.
- Additional properties of the ingestible sheet that are desirable are the ability to remain stable over extended periods of time, at elevated temperatures, and at high or low levels of relative humidity. In addition, it is also preferable that the ingestible sheets are generally a poor medium for the growth of microorganisms to reduce spoilage. Further, ingestible sheets that possess reasonable mechanical properties such as tensile strength and tear strength are desirable to allow the sheets to be processed through the various steps of fabrication of the final dosage form using methods such as are recognized in the art.
- Ingestible sheets that can be utilized in the present invention can be one or a mixture of organic film formers generally classified into two broad categories, i.e. polymeric and paper. Examples of such film formers are starch (i.e. both natural and chemically modified) and glycerin based sheets with or without a releasable backing. Other examples include, proteins such as gelatin, cellulose derivatives such as hydroxypropylmethylcellulose and the like; other polysaccharides such as pectin, xanthan gum, guar gum, algin and the like; synthetic polymers such as polyvinyl alcohol, polyvinylpyrrolidone and the like. Examples of ingestible sheets or edible films that can be utilized are those that are based on milk proteins, rice paper, potato wafer sheets, and films made from restructured fruits and vegetables.
- In particular, sheets or films made from restructured fruits and vegetables are advantageous were it is desirable to mask or modify the taste or smell of the medicament being delivered. Further, these restructured fruit and vegetable films also provide a convenient approach to encourage children to take various medications as well as providing a more pleasing and varied taste for various medications taken by adults. For more information on restructured fruit and vegetable films, see for example U.S. Pat. No. 5,543,164 and U.S. Pat. No. 6,027,758.
- Dispensing the medicament on an ingestible sheet containing a water-expandable foam is preferable for those applications desiring rapid release of the medicament once ingested. Examples of such materials are an oxidized regenerated cellulose commercially available from Johnson and Johnson under the trademark SURGICEL®, and a porcine derived gelatin powder commercially available from Pharmacia Corporation under the trademark GELFOAM®.
- The form of the ingestible sheet that can be utilized in the present invention can be any of the forms generally recognized in the art such as those used for paper, cardboard or polymeric films. The ingestible sheet or roll preferably is uniform in thickness and in width. Although the thickness of the ingestible sheet will depend on the particular medicament being dispensed, the particular ingestible sheet being utilized, and the particular method of manufacture used; the thickness of the ingestible sheet preferably ranges from about 10 to about 350 microns and more preferably from about 25 to about 100 microns thick.
- The dosage forms produced in accordance with the present invention are eminently suited to span the range of production from individualized doses made in a home or hospital environment to the high speed high volume production in a pharmaceutical manufacturing environment. Thus, the particular width and length will not only depend on both the particular medicament being dispensed and the particular ingestible sheet being utilized, but more particularly on the particular method of manufacture used. Thus, the ingestible sheet can be in roll or individual sheet forms with widths varying from approximately one centimeter to several meters, and lengths from a few centimeters to several thousand meters, although other lengths and widths can also be utilized.
- An embodiment of an ingestible sheet that is preferable for both high speed high volume manufacturing as well as for custom, individualized dispensing is illustrated in a perspective view in
FIG. 4 . In this embodiment, aningestible sheet 404 is in the form of a roll that containsperforations 447 that delineates eachdosage form ingestible sheet 404. A sheet advancer (not shown) then advances theingestible sheet 404 and a second two dimensional array or alternate pattern is dispensed on a second portion of the ingestible sheet. The first and second portions form dosage forms 405 and 405′ respectively. - Preferably, after the medicament is dispensed on the
dosage form 405 the user or system separates thedosage form 405 from thedosage form 405′ by tearing, by cutting along theperforations 447, or by punching out the dispensed areas of the sheet. The user or system can also separate thedosage form 405 from thedosage form 405′ before dispensing of the medicament. This embodiment is particularly advantageous for systems such as those that have fixed fluid ejection cartridges; however, it can also be utilized in other systems as well. Preferably, the ejector head is approximately the width of theingestible sheet 404 and the platen (not shown) moves the ingestible sheet in the direction ofarrow 448 allowing both the dispensed dose of medicament as well as the appropriate characters or symbols utilizing the ingestible ink to be formed. - An alternate embodiment of an ingestible sheet that can also be used for custom, individualized pharmaceutical doses is shown in a plan view in
FIG. 5 a and in a cross-sectional view inFIG. 5 b. In this embodiment, aningestible sheet 504 is in the form of a sheet with a plurality ofdosage forms 505 where eachdosage form 505 containsdosage form separators 547 around its peripheral edge. Preferably, after the medicament is dispensed on the plurality of the dosage forms 505 contained in theingestible sheet 504 the user or system separates thedosage form 505 from the dosage forms 505′ and 505″ by bending or, by pushing up in the center of thedosage form 505, or some other convenient method and peeling thedosage form 505 from areleasable backing 549 shown inFIG. 5 b. This embodiment is particularly advantageous for systems used to dispense custom pharmaceutical doses at home, in a hospital or a pharmacy; however, it can also be utilized in other systems as well. AlthoughFIG. 5 a shows theingestible sheet 504 utilizingdosage form separators 547, theingestible sheet 504 can utilize any convenient means of separation such as perforations shown inFIG. 4 . - An embodiment of a method for generating a dosage form where the medicament is dispensed onto the ingestible sheet is shown in a cross-sectional view in
FIG. 6 a. In this embodiment, a drop-firing controller in a fluid dispensing system (not shown) activates one and, typically, a plurality of fluid ejectors, of a fluid ejection cartridge (not shown), to eject fluid drops 650, 650′, and 650″ of the medicament onto aningestible sheet 604 formingdeposits ingestible sheet 604. Although this will occur for non-porous, non-absorbing ingestible sheets, typically, theingestible sheet 604 will be a porous and absorbing material which will allow the medicament to be absorbed into the interior of theingestible sheet 604. Adosage form 605 is generated when the required number of fluid drops of the medicament, to create the desired pharmaceutical dose, have been dispensed on a portion of theingestible sheet 604. Preferably, thedosage form 605 contains a two-dimensional array of thedeposits ingestible sheet 604. However, other arrangements can also be utilized, such as overlapping deposits forming a layer, or a different geometrical arrangement of thedeposits - An alternate embodiment of the present invention where the process used for generating a dosage form includes a barrier material deposited over the medicament is shown in a cross-sectional view in
FIG. 6 b. In this embodiment, the drop-firing controller activates one and, typically, a plurality of fluid or barrier ejectors, to eject fluid drops of a barrier material over thedeposits barrier deposits barrier deposits deposits ingestible sheet 604form dosage form 606. The barrier material acts to seal the medicament from the environment. Depending on the particular medicament dispensed, and the particular ingestible sheet used, the barrier material provides various protective properties, such as humidity protection, protection from oxidation, inactivation, or contamination. The barrier material is an edible coating made from a suitable polymeric material such as a water-soluble polyoxyethylene or cellulose ether derivative. In addition, preferably the barrier material is an inert material, which will not interact with the deposited medicament. Further, the barrier material may also act as an adhesive as will be discussed later. In this embodiment, the fluid ejectors activated by the drop-firing controller are either, a different subgroup of fluid ejectors on the fluid ejection cartridge used to dispense the medicament, or a different fluid ejection cartridge. - An alternate embodiment of the present invention where the process used for generating a dosage form includes ingestible ink deposited over the medicament is shown in a cross-sectional view in
FIG. 6 c. In this embodiment, after the medicament and the barrier material has been deposited onto the surface of theingestible sheet 604, as described above, the drop-firing controller activates one and, typically, a plurality of ink ejectors, to eject fluid drops of an ingestible ink at various locations on theingestible sheet 604 to formdots dots ingestible sheet 604. Thedots barrier deposits deposits ingestible sheet 604form dosage form 607. - An alternate embodiment of the present invention where the process used for generating a dosage form includes deposition of more than one medicament onto the
ingestible sheet 604′ is shown in a cross-sectional view inFIG. 6 d. In this embodiment, thedeposits deposits ingestible sheet 604′ as described above. Next, the drop-firing controller activates one and, typically, a plurality of fluid ejectors, to eject fluid drops of a second medicament on theingestible sheet 604′ to formdeposits - After the second medicament has been dispensed, a second barrier is then formed over the
deposits barrier deposits dosage form 608. Preferably the second barrier material is the same as the first, however, depending on the properties and compatibilities of the first and second medicaments as well as the first barrier material the second barrier material may be different from the first barrier material. AlthoughFIG. 6 d depicts two different medicaments deposited on the ingestible sheet, more than two medicaments can be deposited on an ingestible sheet. -
FIGS. 6 a-6 d depict isolated deposits of the medicament and barrier material being deposited onto the ingestible sheet; however, by depositing overlapping deposits of, either or both, the medicament and barrier material layers of each material can be formed. In addition, the order of deposition can also be varied depending on the particular application. For example, the ingestible ink can be deposited before the medicament and the barrier material. Further, theingestible sheet FIGS. 6 a-6 d can have, either or both, a releasable backing (not shown) or barrier material (not shown) coated on the surface opposite to the surface on which the medicament is dispensed. - An alternate embodiment of the present invention of a process for manufacturing a dosage form containing more than one medicament is shown in a perspective view in
FIG. 7 a. In this embodiment, multipleingestible sheets multiple portions ingestible sheet 704 is then sandwiched between theouter sheets laminated structure 764 where each of themultiple portions portion 761 is above theportion 760 which is above theportion 762. This arrangement forms adosage form 705 that contains multiple medicaments. - Although
FIG. 7 a depicts three layers of ingestible sheet being laminated, laminated structures containing two or more layers can be utilized. Theingestible sheets FIGS. 6 a-6 b can also be utilized. Further, other films such as a barrier film or ingestible adhesive film can also be laminated or coated on the differentingestible sheets laminated structure 764 can further be encapsulated and unitized to formsingle dose 766 as shown in perspective view inFIG. 7 b. - An alternate embodiment of the present invention of a process for manufacturing a dosage form containing more than one medicament is shown in a plan view in
FIG. 7 c. In this embodiment, aningestible sheet 704′ containsmultiple portions 760′, 761′, 762′, and 763 each containing a different medicament deposited thereon. The four multiple portions form adosage form 705′ that contains multiple medicaments. AlthoughFIG. 7 c depicts four multiple portions, theingestible sheet 704′ containing two or more multiple portions can be utilized. The various processes and resultant structures depicted inFIGS. 6 a-6 b can also be utilized in this embodiment. In addition, other films such as a barrier film or ingestible adhesive film can also be laminated or coated on theingestible sheet 704′ to improve various properties such as water vapor transmission rate, acid resistance, or drug release rate depending on the particular medicaments and the particular ingestible sheet being utilized. Further themultiple portions 760′, 761′, 762′ and 763 can also be utilized in thelaminated structure 764 shown inFIG. 7 a by either making a larger dosage form or by folding. - As noted above an expandable foam may be desirable for the rapid release of a medicament once ingested, however, some applications may want to vary the amount of the medicament released over time. An advantage of the present invention is the ability to make dosage forms that can vary the amount of medicament or drug released over time as shown in
FIGS. 8 a-8 c. In an alternate embodiment, shown inFIG. 8 a, a fluid ejection cartridge (not shown) containing at least a medicament ejects the medicament onto aningestible sheet 804 to formdeposits 808 of the medicament dispensed in a two dimensional array over the surface of theingestible sheet 804. In this embodiment, adosage form 805 contains afirst edge 806 having a greater density of thedeposits 808 than asecond edge 807 where the density of thedeposits 808 between thefirst edge 806 andsecond edge 807 varies, forming a gradient of the medicament dispensed on the ingestible sheet. Although as shown inFIG. 8 a the medicament is dispensed in the form ofdeposits 808 over the entire surface ofdosage form 805 other forms can also be utilized such as centering the two dimensional array ofdeposits 808 in a narrower strip in the center of thedosage form 805 running from theedge 806 to theedge 807. Thedosage form 805 is wound into a coil, where theedge 806 having the higher dot density forms the edge contained in the center of the coil and theedge 807 having the lower dot density forms the outer edge of the coil. - As the
ingestible sheet 804 dissolves the radius of the coileddosage form 805 decreases, resulting in a smaller surface area, thus the amount of medicament released can be varied or maintained constant. For example as shown inFIG. 8 a a gradient that increases as the surface area decreases can be used to maintain a constant or increasing release rate depending on the particular gradient used. Thus, in this example the medicament is deposited in a gradient adapted to provide a dosage form that, after being ingested, the amount of the medicament released increases over time. Further, the medicament can also be deposited in a gradient adapted to provide a dosage form that, after being ingested, the amount of the medicament released remains constant over time However, as shown inFIG. 8 b, adosage form 805′ that is coiled in the opposite direction where theedge 807, having the lower dot density, forms the center of the coil and theedge 806, having the higher dot density, forms the exterior surface of the coil; generates a gradient that decreases as the surface area decreases. Such a dosage form can be used to decrease the release rate as a function of time creating a loading dose. Thus, in this example the medicament is deposited in a gradient adapted to provide a dosage form that, after being ingested, the amount of the medicament released decreases over time. - A perspective view of an alternate embodiment of the present invention where repeat dosages are formed is shown in
FIG. 8 c. In this embodiment a fluid ejection cartridge (not shown) containing at least one medicament ejects the medicament onto theingestible sheet 804 to form thedeposits 808 of the medicament dispensed in a two dimensional array overdiscrete portions 809 on the surface of theingestible sheet 804. Thedosage form 805″ is wound into a coil where each of thediscrete portions 809 will release the deposited medicament at different times depending on the thickness of theingestible sheet 804, the rate of dissolution of theingestible sheet 804 and the particular placement of eachdiscrete portion 809 among other variables. This embodiment provides a dosage form where a discrete amount of the medicament is released at either repeatable times or discrete amounts of the medicament is released at different times. Although each of the alternative embodiments shown inFIGS. 8 a-8 c are described in terms of fixed dot size and varying the dot density, other methods can also be utilized such as varying the drop size and keeping the dot density constant. This ability to vary the dosage release rate over time is an advantage over a conventionally formed tablet, which would release less medicament as the diameter of the tablet decreases. Thus, the present disclosure allows for a dosage form where the amount of medicament released over time, increases, decreases, remains constant, is repeatable, or a discrete dose is released at different times. - Referring to
FIGS. 9 a-9 b, an alternate embodiment of the present invention is shown where thedosage form 905 containsuser information 970 to be conveyed to the user or patient. For example,FIG. 9 a depicts theuser information 970 as a clock showing the time the dose is to be taken or administered. In this particular example theuser information 970 is deposited over the two dimensional array of thedeposits 908 of the medicament. However, depending on the particular medicament and the particular ingestible sheet being utilized the medicament can also be deposited over the user information. Another example is shown inFIG. 9 b where the information is a message indicating the name, date, and time to take the medicament. However, theuser information 970 can be any symbol, icon, image, or text or combinations thereof, such as a company logo or cartoon character. Other examples of the type of information that can be conveyed to the user are the name of the medicament, the expiration date, the flavor of the ingestible sheet, or information having some marketing value. In addition, thedosage form 905 can also containmanufacturing information 972 to be used by the manufacturer and/or distributor. For example,FIG. 9 b depicts themanufacturing information 972 as a two-dimensional bar code. Themanufacturing information 972, however, can be any symbol, icon, image, or text or combinations thereof. Examples of various forms are a one-dimensional bar code, a text message, a code, or hologram. Examples of the various types of information that can be utilized in themanufacturing information 972 would be the composition of the ingestible sheet or results of quality control testing, data on compatibility with medicaments, expiration dates, or part tracking information. - A cross-sectional view of an alternate embodiment of the present invention where a
dosage form 1005 is encapsulated in atablet 1079 is shown inFIG. 10 b. In this embodiment, alower die chamber 1074 and anupper die chamber 1076 are substantially filled with anexcipient powder 1078 as shown inFIG. 10 a.Dosage form 1005, which contains the medicament deposited on aningestible sheet 1004, is positioned between the two die chambers such that the excipient powder formulation encases or encloses thedosage form 1005. Compressing thelower die chamber 1074 against theupper die chamber 1076 forms thetablet 1079. Preferably, the tablet is cylindrical with convex outer surfaces typically about 5 to 15 mm. in diameter and about 5 mm. in thickness. However, a variety of regular and irregular shapes and sizes can be utilized, such as elliptoids, cuboids, indentations, polygonoids and other convex and concave surfaces. Optional subsequent processes including dedusting, drying, and coating may be performed. - Depending on the desired pharmacokinetic characteristics of the medicament dispensed on the
ingestible sheet 1004, the excipient formulation may be similar to theingestible sheet 1004 or one may select excipients that are dissimilar to the ingestible sheet to obtain tabletting or pharmacokinetic characteristics unlike theingestible sheet 1004. For example microcrystalline sugar (97% sucrose and 3% maltodextrin) or cellulose, calcium phosphate, and sodium carboxymethylcellulose can be used with a cellulosic-based ingestible sheet. Sugars and corn, wheat, or rice starches can be used with starch-based ingestible sheets. Whereas silica added to improve flowability, stearates for lubrication, and guar gum or gelatin as binders are examples of dissimilar materials. - A preferable excipient formulation for direct compression tabletting of a dosage form made from an ingestible sheet which does not include the weight of the ingestible sheet nor the weight of the medicament dispensed is: about 70 weight percent lactose, about 25 weight percent microcrystalline cellulose, about 2 weight percent di-calcium phosphate dihydrate, 2 weight percent sodium carboxymethylcellulose, about 0.3 weight percent fumed silica and about 0.5 weight percent magnesium stearate. However, excipient ranges in formulations for direct compression tabletting of a dosage form made from an ingestible sheet which does not include the weight of the ingestible sheet nor the weight of the medicament dispensed are 0 to about 80 weight percent sugar, 0 to about 25 weight percent microcyrstalline cellulose, 0 to about 90 weight percent calcium phosphate, about 5 to about 25 weight percent starch, about 1 to about 2 weight percent sodium carboxymethylcellulose, about 0.2 to about 0.3 weight percent silica and about 0.5 to about 1 weight percent magnesium stearate can also be utilized.
- In addition to improve adhesion between the excipient powder formulation and the ingestible sheet the excipient formulation can be modified by adding natural or synthetic polymers such as proteins, carboxymethylcellulose, polyvinylacetate, gelatins, or dextrins can be utilized to improve the adhesive properties of the excipient powder. It is also contemplated that an ingestible adhesive can be dispensed between the two die chambers prior to applying pressure to form the tablet. For example, a monomeric methyl or ethylcyanoacrylate type adhesive can be utilized. Alternatively, the
ingestible sheet 1004 of thedosage form 1005 can be perforated to allow greater contact area betweenexcipient powder 1078 contained in theupper die chamber 1076 and thelower die chamber 1074 or thedosage form 1005 can be formed in the shape of a ring containing an area in the center of thedosage form 1005 that allows the excipient powder in the two chambers to bond. - The process described above for compression tabletting of an ingestible sheet containing a medicament is advantageous over conventional tabletting in that the number of mixing steps can be reduced as well as the need to assure thorough mixing of the excipient with the pharmaceutical material to ensure proper dilution. In addition, flowability and drying criteria of the excipient formulation can also be relaxed.
- An
exemplary system 1100 for the interactive dispensing of a medicament on an ingestible sheet is shown as a schematic diagram inFIG. 11 . In this embodiment aprocessor 1180 is coupled to a drop-firing controller via dispenseinterface 1182. Theprocessor 1180 converts a specified quantity of the medicament to be dispensed into a number of drops or ejections to be activated by the drop-firing controller. This number is transmitted via the dispenseinterface 1182 to the drop-firing controller of themedicament dispensing system 200. The specified quantity of the medicament is then ejected onto the ingestible sheet forming a dosage form. Thesystem 1100 also includes astorage device 1186 and adisplay device 1184 coupled to theprocessor 1180 to store and display information. For example user input information, system parameters, information and parameters associated the ingestible sheet can all be stored onstorage device 1186 and/or displayed ondisplay device 1184. - The
system 1100 having theprocessor 1180,display device 1184, andstorage device 1186 is advantageous over current methods of forming pharmaceutical doses in that it allows a user such as a doctor or pharmacist to generate variable doses as well as custom doses in the convenience of a hospital, pharmacy, or home environment. Further, such a system can also be utilized as a point of sale machine, in such locations as a pharmacy or a supermarket, to allow customers to create variable or custom doses of vitamins, nutritional supplements, or other over-the-counter medications. - In addition, the
system 1100 also includes auser interface 1188 or signal receiver that is coupled to theprocessor 1180 and is also coupled viacommunication channel 1193 to anexternal communication network 1190 as shown inFIG. 11 . Preferably, theexternal communication 1190 is a digital network such as what is commonly referred to as the Internet. Other communication channels such as wireless communication, wireline telephone, digital cable television, as well as other point-to-point, point-to-multipoint, and broadcast communications methods can also be used. The user interface orsignal receiver 1188 receives a signal from a remote signal source specifying information to be utilized bysystem 1100. For example, the remote signal source can specify the quantity of medicament to be dispensed or an authorization code verifying the authority of the user to dispense the medicament. As shown inFIG. 11 , thesystem 1100 can also be coupled to aprovider system 1192 vianetwork 1190. - The
provider system 1192 includes aprovider processor 1181, coupled to aprovider display 1185, aprovider storage device 1187, and aprovider interface 1189. Theprovider interface 1189 is coupled viaprovider channel 1194 to theexternal communication network 1190. Theprovider system 1192 is utilized, for example, by a health care provider such as a doctor, a pharmacist, a nurse, appropriate insurance personnel, or other appropriate health care professional. AlthoughFIG. 11 shows a single provider coupled to thesystem 1100 it also preferable to have multiple providers, such as doctors, pharmacists, nurses, insurance providers, and pharmaceutical manufacturers all coupled to thesystem 1100 over theexternal network 1190. This is particularly advantageous wheresystem 1100 is located in a home where the patient can request information on the medicament and appropriate dosage information from a pharmacist, request information on the ingestible sheet from the manufacturer, and current health information from a doctor or nurse over the network; to form the appropriate pharmaceutical dose for that time or multiple doses to cover a period of the next day to several days or weeks. Such a system also allows potentially adverse drug interactions and individual allergies or intolerances and sensitivities to be flagged. - An exemplary embodiment of an interactive method for generating a dosage form where the medicament is dispensed onto the ingestible sheet is shown as flow diagrams in
FIGS. 12-13 . An overview of the method is shown inFIG. 12 . Instep 1200, the various materials such as the medicament and the ingestible sheet are loaded or inserted into a medicament dispensing system. InStep 1210, information indicative of the materials is read either by the system or by a user who then manually enters the information into the system, such as the composition of the ingestible sheet and the active ingredients of the medicament. Instep 1220, various forms of information are requested by the system such as requesting from the doctor or pharmacist the quantity or dose of the medicament to be dispensed. Instep 1230, various forms of information are specified and then transmitted and received by the system, such as the doctor or pharmacist specifying the quantity or dose of the medicament to be dispensed. Various forms of information are verified instep 1240 such as verifying that the dose is within the correct range. The medicaments as well as other materials such as the barrier material are dispensed on the ingestible sheet instep 1250 providing all of verification steps were successfully completed. Inoptional step 1260, appropriate user and manufacturing information is printed on the ingestible sheet. - A more detailed view of the various steps associated with the
loading step 1200 is shown inFIG. 13 a. Instep 1301, an off-axis medicament container is inserted into the dispensing system where the container, after insertion is fluidically coupled to a medicament reservoir of a semi-permanent cartridge. Either a replaceable or semi-permanent medicament ejection cartridge is inserted in the dispensing system instep 1302. An off-axis ingestible ink container, and either a replaceable or semi-permanent ingestible ink ejection cartridge, are inserted into the dispensing system insteps step 1305. Instep 1306, an ingestible sheet is loaded into the dispensing system. - A more detailed view of the various steps associated with the
reading step 1210 is shown as a flow diagram inFIG. 13 b. Instep 1311, information is read from the ingestible sheet. For example, the composition or the expiration date of the ingestible sheet can be read by the system utilizing an image acquisition system scanning a bar code. Preferably this information is stored in a machine readable form, however, a human perceptible form can also be utilized. Insteps - A more detailed view of the various steps associated with the requesting
step 1220 is shown as a flow diagram inFIG. 13 c. Instep 1321 the quantity of the medicament to be dispensed is requested by the medicament dispensing system. For example, this could be displayed on a display device located in the vicinity of the dispensing system or it can be displayed on a remote display device such a doctor's or pharmacist's office. User information is requested by the system instep 1322. This information is any information about the user, i.e. typically the patient, that can be utilized for example in determining the appropriate dose, such as the patient's height, weight, age, etc. or information that is used by the user in administering the dosage form. Instep 1324, manufacturer's information is requested by the system. This information is any information from the manufacturer of the medicament and/or the ingestible sheet. For example, this information can be the same or similar to that obtained insteps - A more detailed view of the various steps associated with the specifying
step 1230 is shown as a flow diagram inFIG. 13 d. Instep 1331, the quantity of the medicament to be dispensed is specified, for example by a doctor or pharmacist, transmitted to and received by the medicament dispensing system. Instep 1332, dosage information, such as dosage forms that vary the amount of medicament released over time as shown inFIG. 8 , is specified, transmitted to and received by the system. User information is specified transmitted to and received by the system instep 1334. This information is any information about the user, i.e. typically the patient, that can be utilized for example in determining the appropriate dose, such as the patient's height, weight, age, etc. or information that is used by the user in administering the dosage form. Instep 1336, manufacturer's information is specified. This information is any information from the manufacturer of the medicament and/or the ingestible sheet. For example, this information can be the same or similar to that obtained insteps - A more detailed view of the various steps associated with the verifying
step 1240 is shown as a flow diagram inFIG. 13 e. Instep 1341, the dosage quantity is verified.Step 1341 verifies information obtained in a previous step such asstep 1331 or multiple steps is used to verify the dosage specified, is either correct or within an acceptable range. For example, the information accessed from the medicament cartridge instep 1312 is compared to the specified quantity to be dispensed instep 1331. Another example would be the use of a third party authorization key where the dosage quantity is verified utilizing the key that is located on the user's system or is accessed via a network such as the Internet. The dosage information specified instep 1332 is verified instep 1342. For example, if the information has been previously entered then the information specified instep 1332 can be verified from stored information stored on a storage device. However, ifstep 1332 is being performed for the first time with a given user then either the information can be retransmitted back to the person specifying or the information can be verified by a third party such as a doctor or an insurance agent via a network such as the Internet. Instep 1344, user information is verified. This step can also be carried out using either previously stored information or a third party as described above instep 1342. The manufacturer's information is verified instep 1346. This step can also be carried out using either previously stored information or a third party as described above instep 1342. The manufacturer's information is any information from the manufacturer of the medicament or the ingestible sheet obtained insteps 1336 orstep 1210. - A more detailed view of the various steps associated with dosing of the medicament on the ingestible sheet in
step 1250 is shown as a flow diagram inFIG. 13 f provided the verification steps described above have been successfully completed. Instep 1351, the quantity of medicament to be dispensed is converted on a processor into a number of activations of a fluid ejector. The ingestible sheet is advanced into a fluid ejection area beneath the ejector head or heads instep 1352. The dosing data preferably in the form of the number of activations of a fluid ejector is transmitted from the processor to the dispense system instep 1354. Instep 1356, the fluid ejectors are activated to produce the pharmaceutical dose. Preferably, the drops are ejected in a predetermined fluid swath pattern using dot matrix manipulation, forming the pharmaceutical dose from the cartridge containing the medicament, however other processes of firing the fluid ejectors can also be utilized. In addition, a custom medicament dose can also be generated by inputting the user information, the manufacturing information, dosage information, as well as appropriate information from the medicament cartridge into a dose algorithm. The dose algorithm then combines this information in a predetermined manner to generate a custom medicament dose. - A more detailed view of the various steps associated with printing information on the ingestible sheet, in
step 1260, is shown as a flow diagram inFIG. 13 g. Instep 1361, appropriate manufacturing information, such as the composition of the ingestible sheet and the name or the medicament, is printed on the ingestible sheet. The manufacturing information printed instep 1361 can be printed either in a machine understood form instep 1363 or it can be printed in a human perceptible form instep 1362 or in some combination thereof. The user information, such as the name of the user or patient and the date and time for administering the dosage form, is printed on the ingestible sheet instep 1364. Instep 1366, preferably the barrier material is dispensed over the medicament previously dispensed instep 1356. However, depending on the particular ingestible sheet, medicament, and dosage structure (e.g. capsule or laminated structure) being utilized, the barrier material may be dispensed before the medicament is dispensed. - The present invention can advantageously reduce the number of therapeutically inactive materials, the number of dilutions, and the number of mixings in the manufacture of unit dosage forms. In addition, the medicament cartridge and the medicament dispensing system of the present invention provides for the custom dispensing of pharmaceutical unit dosage forms where the type of pharmaceutical and the quantity of the selected drug can be easily varied to meet a specific prescription. The medicament cartridge and the medicament dispensing system of the present invention provides the ability of dispensing multiple, different pharmaceuticals in varied, selected quantities to a single receiving medium thus simplifying the taking of drugs, especially combinations of different drugs by providing multiple drugs in one dose.
Claims (32)
1. A method of applying an orally-ingestible medicament to an orally-ingestible carrier, the method comprising:
controlling a relative position between a fluid ejector and the carrier; and
ejecting a plurality of drops of solution onto the carrier, wherein the plurality of drops includes a desired therapeutic quantity of the orally-ingestible medicament.
2. The method of claim 1 , wherein each of the plurality of drops has substantially the same volume as each other drop of the plurality of drops.
3. The method of claim 2 , wherein each of the plurality of drops has a volume at most 10% different than a volume of each other drop of the plurality of drops.
4. The method of claim 2 , wherein each of the plurality of drops has a volume at most 6% different than a volume of each other drop of the plurality of drops.
5. The method of claim 2 , wherein each of the plurality of drops includes substantially equal amounts of orally-ingestible medicament.
6. The method of claim 5 , wherein each of the plurality of drops has an amount of orally-ingestible medicament at most 10% different than an amount of orally-ingestible medicament of each other drop of the plurality of drops.
7. The method of claim 5 , wherein each of the plurality of drops has an amount of orally-ingestible medicament at most 6% different than an amount of orally-ingestible medicament of each other drop of the plurality of drops.
8. The method of claim 1 , wherein ejecting a plurality of drops includes ejecting a number of drops selected to yield the desired therapeutic quantity of the orally-ingestible medicament.
9. The method of claim 1 , wherein the desired therapeutic quantity is within a range no more than 1% greater or less than a target dose.
10. The method of claim 1 , further comprising printing information onto the orally-ingestible sheet.
11. The method of claim 10 , wherein printing includes printing the information onto the orally-ingestible sheet in a machine detectable form.
12. The method of claim 10 , wherein printing includes printing the information onto the orally-ingestible sheet in a human-perceptible form.
13. The method of claim 1 , further comprising sealing the orally-ingestible medicament on the orally-ingestible sheet.
14. The method of claim 13 , wherein sealing includes activating a fluid ejector to eject a barrier component fluid over the orally-ingestible medicament.
15. An edible dosage form produced by the method of claim 1 .
16. A method of applying an orally-ingestible medicament on an orally-ingestible sheet, comprising:
advancing the orally-ingestible sheet to a dispense position; and
activating a fluid ejector to eject the orally-ingestible medicament onto the orally-ingestible sheet.
17. The method of claim 16 , further comprising printing information onto the orally-ingestible sheet.
18. The method of claim 17 , wherein printing includes printing the information onto the orally-ingestible sheet in a machine detectable form.
19. The method of claim 17 , wherein printing includes printing the information onto the orally-ingestible sheet in a human-perceptible form.
20. The method of claim 17 , wherein printing includes ejecting an orally-ingestible ink from at least one ink ejector fluidically coupled to an ink reservoir onto the orally-ingestible sheet.
21. The method of claim 16 , wherein activating includes activating the fluid ejector to eject a predetermined number of ejections of the orally-ingestible medicament.
22. The method of claim 16 , further comprising sealing the orally-ingestible medicament on the orally-ingestible sheet.
23. The method of claim 21 , wherein sealing includes activating a barrier fluid ejector to eject a barrier component fluid over the orally-ingestible medicament.
24. An edible dosage form produced by the method of claim 16 .
25. A method of applying an orally-ingestible medicament on an orally-ingestible sheet, comprising:
receiving a fluid ejection cartridge into a fluid dispensing system, the cartridge holding a mixture of an orally-ingestible ink and an orally-ingestible medicament;
advancing the orally-ingestible sheet to a dispense position; and
printing a user message on the orally-ingestible sheet using the mixture of the orally-ingestible ink and the orally-ingestible medicament.
26. An edible dosage form produced by the method of claim 25 .
27. A method of manufacturing an orally-ingestible dose, comprising:
advancing an orally-ingestible sheet having at least one dosage region to a dispense position; and
activating a fluid ejector to eject a two-dimensional array of an orally-ingestible medicament onto the dosage region of the orally-ingestible sheet, wherein the dosage region includes a first edge and a second edge, and wherein a density of the two-dimensional array of the orally-ingestible medicament varies between the first edge and the second edge, forming a two-dimensional gradient of orally-ingestible medicament.
28. The method of claim 27 , further comprising coating a deposited array of ingestible medicament with an ingestible coating material.
29. The method of claim 28 , wherein coating the deposited array includes activating a second fluid ejector to eject an ingestible barrier component fluid over the deposited array of ingestible medicament.
30. An edible dosage form produced by the method of claim 27 .
31. A method of manufacturing an orally-ingestible dosage form, comprising:
advancing an orally-ingestible sheet having at least one dosage region to a dispense position;
activating a fluid ejector to eject a first two-dimensional array of an orally-ingestible medicament onto the dosage region of the orally-ingestible sheet;
dispensing an orally-ingestible barrier layer on the first two-dimensional array of orally-ingestible medicament; and
activating the fluid ejector to eject a second two-dimensional array of orally-ingestible medicament on the orally-ingestible barrier layer, thus forming a three-dimensional array of orally-ingestible medicament on the orally-ingestible sheet.
32. An edible dosage form produced by the method of claim 31.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/048,368 US20050129746A1 (en) | 2001-10-24 | 2005-01-31 | Fluid-jet medicament delivery |
US13/098,854 US20110204085A1 (en) | 2001-10-24 | 2011-05-02 | Fluid-jet medicament delivery |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/028,450 US6962715B2 (en) | 2001-10-24 | 2001-10-24 | Method and dosage form for dispensing a bioactive substance |
US11/048,368 US20050129746A1 (en) | 2001-10-24 | 2005-01-31 | Fluid-jet medicament delivery |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/028,450 Continuation-In-Part US6962715B2 (en) | 2001-06-07 | 2001-10-24 | Method and dosage form for dispensing a bioactive substance |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/098,854 Continuation US20110204085A1 (en) | 2001-10-24 | 2011-05-02 | Fluid-jet medicament delivery |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050129746A1 true US20050129746A1 (en) | 2005-06-16 |
Family
ID=21843509
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/028,450 Expired - Lifetime US6962715B2 (en) | 2001-06-07 | 2001-10-24 | Method and dosage form for dispensing a bioactive substance |
US11/048,368 Abandoned US20050129746A1 (en) | 2001-10-24 | 2005-01-31 | Fluid-jet medicament delivery |
US11/111,240 Active 2028-05-12 US8454989B2 (en) | 2001-10-24 | 2005-04-20 | Laminated ingestible dosage form for dispensing multiple bioactive substances |
US13/098,854 Abandoned US20110204085A1 (en) | 2001-10-24 | 2011-05-02 | Fluid-jet medicament delivery |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/028,450 Expired - Lifetime US6962715B2 (en) | 2001-06-07 | 2001-10-24 | Method and dosage form for dispensing a bioactive substance |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/111,240 Active 2028-05-12 US8454989B2 (en) | 2001-10-24 | 2005-04-20 | Laminated ingestible dosage form for dispensing multiple bioactive substances |
US13/098,854 Abandoned US20110204085A1 (en) | 2001-10-24 | 2011-05-02 | Fluid-jet medicament delivery |
Country Status (4)
Country | Link |
---|---|
US (4) | US6962715B2 (en) |
EP (4) | EP1306071B1 (en) |
DE (4) | DE60221056T2 (en) |
HK (1) | HK1053259B (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060000470A1 (en) * | 2004-06-09 | 2006-01-05 | Clarke Allan J | Apparatus and method for producing a pharmaceutical product |
US20060002594A1 (en) * | 2004-06-09 | 2006-01-05 | Clarke Allan J | Method for producing a pharmaceutical product |
US20060001866A1 (en) * | 2004-06-09 | 2006-01-05 | Clarke Allan J | Apparatus and method for producing or processing a product or sample |
US20070231427A1 (en) * | 2006-03-29 | 2007-10-04 | Wm Wrigley Jr. Company | Spray-formed confectionery product, apparatus and method |
US20090162435A1 (en) * | 2007-12-21 | 2009-06-25 | Bunick Frank J | Manufacture of tablet |
US7976872B2 (en) | 2006-07-24 | 2011-07-12 | L. Perrigo Company | Method for distributing a pharmaceutically active compound in an excipient |
US20130236374A1 (en) * | 2012-03-09 | 2013-09-12 | John Glenn Edelen | Fluid cartridge and system for dispensing fluid |
WO2014120992A1 (en) * | 2013-02-01 | 2014-08-07 | International Flavors & Fragrances Inc. | Method of flavor or fragrance microdosing |
US9168223B2 (en) | 2010-12-23 | 2015-10-27 | Tailorpill Technologies, Llc | Custom-pill compounding system with filler-free capability |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040173146A1 (en) * | 2001-06-07 | 2004-09-09 | Figueroa Iddys D. | Application of a bioactive agent to a delivery substrate |
US20040173147A1 (en) * | 2001-06-07 | 2004-09-09 | Figueroa Iddys D. | Application of a bioactive agent to a delivery substrate |
US6962715B2 (en) * | 2001-10-24 | 2005-11-08 | Hewlett-Packard Development Company, L.P. | Method and dosage form for dispensing a bioactive substance |
US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
US20070281003A1 (en) | 2001-10-12 | 2007-12-06 | Fuisz Richard C | Polymer-Based Films and Drug Delivery Systems Made Therefrom |
US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
US20190328679A1 (en) | 2001-10-12 | 2019-10-31 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US7727576B2 (en) * | 2004-04-16 | 2010-06-01 | Hewlett-Packard Development Company, L.P. | System and a method for producing layered oral dosage forms |
AU2011204851B2 (en) * | 2004-06-09 | 2012-11-29 | Glaxosmithkline Llc | Apparatus and method for pharmaceutical production |
US20060002986A1 (en) * | 2004-06-09 | 2006-01-05 | Smithkline Beecham Corporation | Pharmaceutical product |
AU2011204848B2 (en) * | 2004-06-09 | 2012-11-29 | Glaxosmithkline Llc | Apparatus and method for pharmaceutical production |
US20060008507A1 (en) * | 2004-07-06 | 2006-01-12 | Gore Makarand P | System for generating a bioactive dosage form |
US20060104910A1 (en) * | 2004-11-15 | 2006-05-18 | Keith Lerner | Over dosage indicating medicated film strip |
DE112007000162T5 (en) * | 2006-01-19 | 2008-11-27 | Toray Engineering Co., Ltd. | Laminated microcapsule sheet and method of making the same |
US20080026040A1 (en) * | 2006-07-31 | 2008-01-31 | Isaac Farr | Active agent-releasing dosage forms |
US20080026062A1 (en) * | 2006-07-31 | 2008-01-31 | Isaac Farr | Pharmaceutical compositions including nano-sized active agent |
WO2008053683A1 (en) * | 2006-10-12 | 2008-05-08 | Toray Engineering Co., Ltd. | Microcapsule sheet |
DE102006054638B4 (en) * | 2006-11-16 | 2014-12-04 | Laburnum Gmbh | Pharmaceutical single-dose form |
EP2259803B2 (en) | 2008-02-29 | 2019-03-13 | Ferrosan Medical Devices A/S | Device for promotion of hemostasis and/or wound healing |
US8799010B2 (en) * | 2008-05-07 | 2014-08-05 | Unitedhealth Group Incorporated | Telehealth scheduling and communications network |
WO2010012470A1 (en) * | 2008-07-30 | 2010-02-04 | Research Center Pharmaceutical Engineering Gmbh | A system and method for manufacturing a medication |
US20100155494A1 (en) * | 2008-12-18 | 2010-06-24 | Pitney Bowes Inc. | Print containment of pixels to improve readability |
US20100178254A1 (en) * | 2009-01-13 | 2010-07-15 | Monosol Rx Llc | Unit assembly for multiple film dosages, apparatus, and methods |
DE102010009071A1 (en) | 2010-02-23 | 2011-10-06 | Optimags Dr. Zimmermann Gmbh | Preparing edible film useful for oral bioactivator, involves dissolving polyethylene glycol and sugar in water, and adding and mixing glycerol with polyethylene glycol-sugar solution |
US20110290694A1 (en) * | 2010-05-27 | 2011-12-01 | Monosol Rx, Llc | Oral film dosage form having indicia thereon |
US9149959B2 (en) | 2010-10-22 | 2015-10-06 | Monosol Rx, Llc | Manufacturing of small film strips |
DE102011088909A1 (en) * | 2011-08-12 | 2013-02-14 | Labtec Gmbh | Process for the preparation and control of oral drug films |
WO2013062570A1 (en) * | 2011-10-28 | 2013-05-02 | Hewlett-Packard Development Company, L.P. | Apparatus and method for producing controlled dosage of bioactive agent |
EP2822474B1 (en) | 2012-03-06 | 2018-05-02 | Ferrosan Medical Devices A/S | Pressurized container containing haemostatic paste |
WO2013185776A1 (en) | 2012-06-12 | 2013-12-19 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
WO2014000803A1 (en) | 2012-06-28 | 2014-01-03 | Optimags Dr. Zimmermann Gmbh | Method for producing a film formulation for an edible film, and the use thereof |
WO2014116770A1 (en) * | 2013-01-23 | 2014-07-31 | Arx, Llc | Production of unit dose constructs |
JP6390873B2 (en) | 2013-06-21 | 2018-09-19 | フェッローサン メディカル ディバイス エー/エス | Dry composition expanded under reduced pressure and syringe for holding the same |
CN105828844B (en) | 2013-12-11 | 2019-09-27 | 弗罗桑医疗设备公司 | Dry composition comprising squeezing out reinforcing agent |
WO2016058612A1 (en) | 2014-10-13 | 2016-04-21 | Ferrosan Medical Devices A/S | Dry composition for use in haemostasis and wound healing |
EP3237041B1 (en) | 2014-12-24 | 2020-01-29 | Ferrosan Medical Devices A/S | Syringe for retaining and mixing first and second substances |
KR101547219B1 (en) * | 2014-12-31 | 2015-08-25 | (주)씨엘팜 | Method and apparatus for producing oral dispersible film with multi low and formulated drug |
US10653622B1 (en) | 2015-04-13 | 2020-05-19 | Pharmacoustics Technologies LLC | Individualized solid dosage products and a system and method for the globally integrated pharmaceutical manufacturing and its monitoring thereof |
AU2016290433B2 (en) | 2015-07-03 | 2018-05-24 | Ferrosan Medical Devices A/S | Syringe for mixing two components and for retaining a vacuum in a storage condition |
US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
CA3022840A1 (en) | 2016-05-05 | 2017-11-09 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
ES2968412T3 (en) | 2018-05-09 | 2024-05-09 | Ferrosan Medical Devices As | Method for preparing a hemostatic composition |
US20220023228A1 (en) * | 2020-07-21 | 2022-01-27 | Bryan Daniel Haynes | Edible Graphic Drug Delivery System and Method of Manufacture |
WO2022093211A1 (en) * | 2020-10-28 | 2022-05-05 | Hewlett-Packard Development Company, L.P. | Self-wicking assay devices |
WO2022093214A1 (en) * | 2020-10-28 | 2022-05-05 | Hewlett-Packard Development Company, L.P. | Fluid degradable barrier valves for self-wicking substrates |
Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3625214A (en) * | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
US4197289A (en) * | 1975-12-15 | 1980-04-08 | Hoffmann-La Roche Inc. | Novel dosage forms |
US4285978A (en) * | 1979-03-21 | 1981-08-25 | Quinlivan Sharon L | Method for decorating baked goods and the like |
US4322449A (en) * | 1978-11-15 | 1982-03-30 | Boehringer Ingelheim Gmbh | Pharmaceuticals having dotted active ingredients and a method and apparatus for the preparation thereof |
US4548825A (en) * | 1978-11-15 | 1985-10-22 | Boehringer Ingelheim Gmbh | Method for ink-jet printing on uncoated tablets or uncoated tablet cores |
US4771295A (en) * | 1986-07-01 | 1988-09-13 | Hewlett-Packard Company | Thermal ink jet pen body construction having improved ink storage and feed capability |
US4925670A (en) * | 1986-09-09 | 1990-05-15 | Desitin Arzneimittel Gmbh | Administration and dosage form for drug active agents, reagents or the like and process for the preparation thereof |
US5021802A (en) * | 1988-02-19 | 1991-06-04 | Dataproducts Corporation | Thermally reversible sol-gel phase change ink or bubble jet ink |
US5070410A (en) * | 1989-03-21 | 1991-12-03 | Hewlett-Packard Company | Apparatus and method using a combined read/write head for processing and storing read signals and for providing firing signals to thermally actuated ink ejection elements |
US5505775A (en) * | 1993-09-29 | 1996-04-09 | Kitos; John | Cake decorating system |
US5511726A (en) * | 1988-09-23 | 1996-04-30 | Battelle Memorial Institute | Nebulizer device |
US5543164A (en) * | 1994-06-17 | 1996-08-06 | The Regents Of The University Of California | Water-insoluble protein-based edible barrier coatings and films |
US5609908A (en) * | 1991-02-05 | 1997-03-11 | Voss; Gunter | Apparatus for coating a pressing chamber with a lubricant |
US5699649A (en) * | 1996-07-02 | 1997-12-23 | Abrams; Andrew L. | Metering and packaging device for dry powders |
US5714007A (en) * | 1995-06-06 | 1998-02-03 | David Sarnoff Research Center, Inc. | Apparatus for electrostatically depositing a medicament powder upon predefined regions of a substrate |
US5881716A (en) * | 1995-09-21 | 1999-03-16 | Pelikan Produktions Ag | Device for dosing of liquid |
US5894841A (en) * | 1993-06-29 | 1999-04-20 | Ponwell Enterprises Limited | Dispenser |
US5925732A (en) * | 1994-09-21 | 1999-07-20 | Isis Pharmaceuticals, Inc. | Chemical reaction apparatus for performing multiple reaction on a surface and collecting the product |
US5960609A (en) * | 1998-06-12 | 1999-10-05 | Microdose Technologies, Inc. | Metering and packaging method and device for pharmaceuticals and drugs |
US5992890A (en) * | 1997-06-20 | 1999-11-30 | Medical Media Information Bv | Method of prescribing pharmaceuticals and article of commerce therefor |
US6027758A (en) * | 1996-09-12 | 2000-02-22 | The United States Of America As Represented By The Secretary Of Agriculture | Restructured fruit and vegetable products and processing methods |
US6063412A (en) * | 1995-08-07 | 2000-05-16 | Hoy; Stephen B. | Edible animal greeting cards |
US6086942A (en) * | 1998-05-27 | 2000-07-11 | International Brachytherapy S.A. | Fluid-jet deposition of radioactive material for brachytherapy devices |
US6280771B1 (en) * | 1997-02-20 | 2001-08-28 | Therics, Inc. | Dosage forms exhibiting multi-phasic release kinetics and methods of manufacture thereof |
US6440669B1 (en) * | 1999-11-10 | 2002-08-27 | Agilent Technologies, Inc. | Methods for applying small volumes of reagents |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE637363A (en) | ||||
BE825842A (en) * | 1974-02-22 | 1975-08-21 | PHARMACEUTICAL COMPOSITIONS INCLUDING DIGOXIN | |
CH624846A5 (en) | 1975-12-15 | 1981-08-31 | Hoffmann La Roche | Solid pharmaceutical unit dose form and process and apparatus for producing it |
US4826689A (en) * | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5209933A (en) * | 1990-01-10 | 1993-05-11 | Syntex (U.S.A.) Inc. | Long acting calcium channel blocker composition |
US5046618A (en) * | 1990-11-19 | 1991-09-10 | R. P. Scherer Corporation | Child-resistant blister pack |
US5552160A (en) * | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5286497A (en) * | 1991-05-20 | 1994-02-15 | Carderm Capital L.P. | Diltiazem formulation |
GB9119052D0 (en) * | 1991-09-06 | 1991-10-23 | Boots Co Plc | Pharmaceutical compositions |
US6616958B1 (en) * | 1993-07-07 | 2003-09-09 | Jack Guttman, Inc. | Method of making and using an edible film for decorating foodstuffs |
US5490962A (en) * | 1993-10-18 | 1996-02-13 | Massachusetts Institute Of Technology | Preparation of medical devices by solid free-form fabrication methods |
US5992742A (en) * | 1994-08-05 | 1999-11-30 | Sullivan; Scott L. | Pill printing and identification |
US6551611B2 (en) * | 1995-09-28 | 2003-04-22 | Schering Aktiengesellschaft | Hormone replacement therapy method |
US5797898A (en) * | 1996-07-02 | 1998-08-25 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
KR19990001564A (en) * | 1997-06-16 | 1999-01-15 | 유충식 | Azole antifungal agents with improved solubility and preparations containing them |
GB2338896B (en) * | 1998-07-02 | 2003-05-21 | Reckitt & Colmann Prod Ltd | Chewable Capsules |
UA74141C2 (en) * | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Oral pharmaceutical compositions comprising micronized eplerenone (variants), method for its production and method for treating aldosterone-mediated states (variants) |
US6689319B1 (en) | 1999-10-29 | 2004-02-10 | Agilent Technologies, Ind. | Apparatus for deposition and inspection of chemical and biological fluids |
US6474786B2 (en) * | 2000-02-24 | 2002-11-05 | The Board Of Trustees Of The Leland Stanford Junior University | Micromachined two-dimensional array droplet ejectors |
US6962715B2 (en) * | 2001-10-24 | 2005-11-08 | Hewlett-Packard Development Company, L.P. | Method and dosage form for dispensing a bioactive substance |
US7767249B2 (en) * | 2001-06-07 | 2010-08-03 | Hewlett-Packard Development Company, L.P. | Preparation of nanoparticles |
US6623785B2 (en) * | 2001-06-07 | 2003-09-23 | Hewlett-Packard Development Company, L.P. | Pharmaceutical dispensing apparatus and method |
US6702894B2 (en) * | 2001-10-24 | 2004-03-09 | Hewlett-Packard Development Company, L.P. | Fluid ejection cartridge and system for dispensing a bioactive substance |
-
2001
- 2001-10-24 US US10/028,450 patent/US6962715B2/en not_active Expired - Lifetime
-
2002
- 2002-10-03 EP EP02256920A patent/EP1306071B1/en not_active Expired - Lifetime
- 2002-10-03 DE DE60221056T patent/DE60221056T2/en not_active Expired - Lifetime
- 2002-10-03 DE DE60224113T patent/DE60224113T2/en not_active Expired - Lifetime
- 2002-10-03 DE DE60217258T patent/DE60217258T2/en not_active Expired - Lifetime
- 2002-10-03 DE DE60224111T patent/DE60224111T2/en not_active Expired - Lifetime
- 2002-10-03 EP EP05076409A patent/EP1584318B1/en not_active Expired - Lifetime
- 2002-10-03 EP EP05076410A patent/EP1582192B1/en not_active Expired - Lifetime
- 2002-10-03 EP EP05076408A patent/EP1582191B1/en not_active Expired - Lifetime
-
2003
- 2003-07-24 HK HK03105362.6A patent/HK1053259B/en not_active IP Right Cessation
-
2005
- 2005-01-31 US US11/048,368 patent/US20050129746A1/en not_active Abandoned
- 2005-04-20 US US11/111,240 patent/US8454989B2/en active Active
-
2011
- 2011-05-02 US US13/098,854 patent/US20110204085A1/en not_active Abandoned
Patent Citations (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3625214A (en) * | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
US4197289A (en) * | 1975-12-15 | 1980-04-08 | Hoffmann-La Roche Inc. | Novel dosage forms |
US4322449A (en) * | 1978-11-15 | 1982-03-30 | Boehringer Ingelheim Gmbh | Pharmaceuticals having dotted active ingredients and a method and apparatus for the preparation thereof |
US4548825A (en) * | 1978-11-15 | 1985-10-22 | Boehringer Ingelheim Gmbh | Method for ink-jet printing on uncoated tablets or uncoated tablet cores |
US4285978A (en) * | 1979-03-21 | 1981-08-25 | Quinlivan Sharon L | Method for decorating baked goods and the like |
US4771295A (en) * | 1986-07-01 | 1988-09-13 | Hewlett-Packard Company | Thermal ink jet pen body construction having improved ink storage and feed capability |
US4771295B1 (en) * | 1986-07-01 | 1995-08-01 | Hewlett Packard Co | Thermal ink jet pen body construction having improved ink storage and feed capability |
US4925670A (en) * | 1986-09-09 | 1990-05-15 | Desitin Arzneimittel Gmbh | Administration and dosage form for drug active agents, reagents or the like and process for the preparation thereof |
US5021802A (en) * | 1988-02-19 | 1991-06-04 | Dataproducts Corporation | Thermally reversible sol-gel phase change ink or bubble jet ink |
US5511726A (en) * | 1988-09-23 | 1996-04-30 | Battelle Memorial Institute | Nebulizer device |
US5070410A (en) * | 1989-03-21 | 1991-12-03 | Hewlett-Packard Company | Apparatus and method using a combined read/write head for processing and storing read signals and for providing firing signals to thermally actuated ink ejection elements |
US5609908A (en) * | 1991-02-05 | 1997-03-11 | Voss; Gunter | Apparatus for coating a pressing chamber with a lubricant |
US5894841A (en) * | 1993-06-29 | 1999-04-20 | Ponwell Enterprises Limited | Dispenser |
US5505775A (en) * | 1993-09-29 | 1996-04-09 | Kitos; John | Cake decorating system |
US5543164A (en) * | 1994-06-17 | 1996-08-06 | The Regents Of The University Of California | Water-insoluble protein-based edible barrier coatings and films |
US5925732A (en) * | 1994-09-21 | 1999-07-20 | Isis Pharmaceuticals, Inc. | Chemical reaction apparatus for performing multiple reaction on a surface and collecting the product |
US6007630A (en) * | 1995-06-06 | 1999-12-28 | David Sarnoff Research Center Inc. | Method and apparatus for electrostatically depositing a medicament powder upon predefined regions of a substrate |
US5714007A (en) * | 1995-06-06 | 1998-02-03 | David Sarnoff Research Center, Inc. | Apparatus for electrostatically depositing a medicament powder upon predefined regions of a substrate |
US6074688A (en) * | 1995-06-06 | 2000-06-13 | Delsys Pharmaceautical Corporation | Method for electrostatically depositing a medicament powder upon predefined regions of a substrate |
US6063412A (en) * | 1995-08-07 | 2000-05-16 | Hoy; Stephen B. | Edible animal greeting cards |
US5881716A (en) * | 1995-09-21 | 1999-03-16 | Pelikan Produktions Ag | Device for dosing of liquid |
US5699649A (en) * | 1996-07-02 | 1997-12-23 | Abrams; Andrew L. | Metering and packaging device for dry powders |
US6027758A (en) * | 1996-09-12 | 2000-02-22 | The United States Of America As Represented By The Secretary Of Agriculture | Restructured fruit and vegetable products and processing methods |
US6280771B1 (en) * | 1997-02-20 | 2001-08-28 | Therics, Inc. | Dosage forms exhibiting multi-phasic release kinetics and methods of manufacture thereof |
US5992890A (en) * | 1997-06-20 | 1999-11-30 | Medical Media Information Bv | Method of prescribing pharmaceuticals and article of commerce therefor |
US6086942A (en) * | 1998-05-27 | 2000-07-11 | International Brachytherapy S.A. | Fluid-jet deposition of radioactive material for brachytherapy devices |
US5960609A (en) * | 1998-06-12 | 1999-10-05 | Microdose Technologies, Inc. | Metering and packaging method and device for pharmaceuticals and drugs |
US6440669B1 (en) * | 1999-11-10 | 2002-08-27 | Agilent Technologies, Inc. | Methods for applying small volumes of reagents |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8101244B2 (en) | 2004-06-09 | 2012-01-24 | Smithkline Beecham Corporation | Apparatus and method for producing or processing a product or sample |
US20060002594A1 (en) * | 2004-06-09 | 2006-01-05 | Clarke Allan J | Method for producing a pharmaceutical product |
US20060001866A1 (en) * | 2004-06-09 | 2006-01-05 | Clarke Allan J | Apparatus and method for producing or processing a product or sample |
US20060016830A1 (en) * | 2004-06-09 | 2006-01-26 | Smithkline Beecham Corporation | Apparatus and method for pharmaceutical production |
US20060017916A1 (en) * | 2004-06-09 | 2006-01-26 | Clarke Allan J | Apparatus for producing a pharmaceutical product |
US8252234B2 (en) | 2004-06-09 | 2012-08-28 | Smithkline Beecham Corporation | Apparatus for producing a pharmaceutical product |
US20060000470A1 (en) * | 2004-06-09 | 2006-01-05 | Clarke Allan J | Apparatus and method for producing a pharmaceutical product |
US8122849B2 (en) | 2004-06-09 | 2012-02-28 | Smithkline Beecham Corporation | Apparatus and method for producing a pharmaceutical product |
US20070231432A1 (en) * | 2006-03-29 | 2007-10-04 | Wm Wrigley Jr. Company | Sales methods for a printed comestible product |
US20070231435A1 (en) * | 2006-03-29 | 2007-10-04 | Wm Wrigley Jr. Company | Non-contact printed edible product and method for producing same |
US20070231427A1 (en) * | 2006-03-29 | 2007-10-04 | Wm Wrigley Jr. Company | Spray-formed confectionery product, apparatus and method |
US10092020B2 (en) | 2006-03-29 | 2018-10-09 | Wm. Wrigley Jr. Company | Non-contact printed comestible products and apparatus and method for producing same |
US9226513B2 (en) | 2006-03-29 | 2016-01-05 | Wm. Wrigley Jr. Company | Non-contact printed comestible products and apparatus and method for producing same |
US9044037B2 (en) | 2006-03-29 | 2015-06-02 | Wm. Wrigley Jr. Company | Non-contact printed comestible products and apparatus and method for producing same |
US7976872B2 (en) | 2006-07-24 | 2011-07-12 | L. Perrigo Company | Method for distributing a pharmaceutically active compound in an excipient |
US20090162435A1 (en) * | 2007-12-21 | 2009-06-25 | Bunick Frank J | Manufacture of tablet |
US8357395B2 (en) | 2007-12-21 | 2013-01-22 | Mcneil-Ppc, Inc. | Manufacture of tablet |
US9168223B2 (en) | 2010-12-23 | 2015-10-27 | Tailorpill Technologies, Llc | Custom-pill compounding system with filler-free capability |
US9693932B2 (en) | 2010-12-23 | 2017-07-04 | Tailorpill Technologies, Llc | Method of making a pharmacy compounding system |
US9757308B2 (en) | 2010-12-23 | 2017-09-12 | Tailorpill Technologies, Llc | Cartridge-based pharmacy compounding system |
US9533302B2 (en) * | 2012-03-09 | 2017-01-03 | Lexmark International, Inc. | Fluid cartridge and system for dispensing fluid |
US20130236374A1 (en) * | 2012-03-09 | 2013-09-12 | John Glenn Edelen | Fluid cartridge and system for dispensing fluid |
CN104955652A (en) * | 2013-02-01 | 2015-09-30 | 国际香料和香精公司 | Method of flavor or fragrance microdosing |
WO2014120992A1 (en) * | 2013-02-01 | 2014-08-07 | International Flavors & Fragrances Inc. | Method of flavor or fragrance microdosing |
Also Published As
Publication number | Publication date |
---|---|
US8454989B2 (en) | 2013-06-04 |
HK1053259A1 (en) | 2003-10-17 |
EP1584318A3 (en) | 2006-01-04 |
US20030077315A1 (en) | 2003-04-24 |
EP1582192B1 (en) | 2007-12-12 |
EP1306071B1 (en) | 2007-01-03 |
US20050186253A1 (en) | 2005-08-25 |
DE60217258D1 (en) | 2007-02-15 |
DE60224113D1 (en) | 2008-01-24 |
EP1584318B1 (en) | 2007-07-04 |
EP1582191B1 (en) | 2007-12-12 |
HK1053259B (en) | 2007-04-27 |
EP1306071A2 (en) | 2003-05-02 |
DE60217258T2 (en) | 2007-07-12 |
EP1582192A1 (en) | 2005-10-05 |
DE60224113T2 (en) | 2008-05-21 |
DE60221056D1 (en) | 2007-08-16 |
DE60224111T2 (en) | 2008-11-27 |
EP1306071A3 (en) | 2003-12-03 |
EP1584318A2 (en) | 2005-10-12 |
EP1582191A1 (en) | 2005-10-05 |
US20110204085A1 (en) | 2011-08-25 |
DE60224111D1 (en) | 2008-01-24 |
DE60221056T2 (en) | 2008-02-28 |
US6962715B2 (en) | 2005-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6962715B2 (en) | Method and dosage form for dispensing a bioactive substance | |
US6702894B2 (en) | Fluid ejection cartridge and system for dispensing a bioactive substance | |
Alomari et al. | Personalised dosing: Printing a dose of one’s own medicine | |
EP1413434B1 (en) | Pharmaceutical dosage form and method of making | |
JP2007512095A5 (en) | ||
EP2313050B1 (en) | A system and method for manufacturing a medication | |
CN105534713A (en) | Prescription-applied drug 3D printing system and method | |
EP1648707A2 (en) | Application of a bioactive agent to a delivery substrate | |
US20060008507A1 (en) | System for generating a bioactive dosage form | |
KR20150078774A (en) | Methods and device for making drugs with 3D printing technique | |
WO2005009737A1 (en) | Dot-topography control of dissolution rate of bioactive agents | |
US20220401303A1 (en) | Personalized Medicament Delivery Product | |
Alomari | Application of thermal inkjet systems: Personalised dosing of medicines | |
US20180369072A1 (en) | Film Dispensing Device For Delivery Of An Active Ingredient | |
Preis | Towards printing of medicine in 2D and 3D |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P., TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEE, BRIAN CRAIG;STEINFIELD, STEVEN W.;CHILDERS, WINTHROP D.;AND OTHERS;REEL/FRAME:016244/0853;SIGNING DATES FROM 20050105 TO 20050121 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |